Page last updated: 2024-08-21

thiazoles and Atrial Fibrillation

thiazoles has been researched along with Atrial Fibrillation in 396 studies

Research

Studies (396)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.25)	18.2507
2000's	3 (0.76)	29.6817
2010's	286 (72.22)	24.3611
2020's	106 (26.77)	2.80

Authors

Authors	Studies
Aoyama, T; Enomoto, A; Kawano, Y; Mano, Y; Nagata, M; Nishikawa, T; Sasaki, Y; Takahashi, H	1
Fukuoka, H; Hoshida, S; Inoue, S; Inui, H; Minamisaka, T; Mine, K; Shinoda, Y; Tachibana, K; Ueno, K; Watanabe, T	1
Brüggenjürgen, B; Gao, X; Marston, XL; Unverdorben, M; Wang, R; Ye, X; Yeh, YC; Zimmermann, L	1
Abe, K; Amano, H; Asaoka, Y; Honda, T; Kodashima, S; Komatsuda, S; Kozuma, K; Manabe, D; Tanaka, A; Yamamoto, H; Yamamoto, T; Yanagisawa, D	1
Duggal, A; Grosso, MA; Kakkar, T; Kotsuma, M; Lanz, H; Shi, M; Yin, O	1
Antman, EM; Bonaca, MP; Braunwald, E; Cunningham, JW; Giugliano, RP; Grosso, MA; Halperin, JL; Lanz, HJ; Murphy, SA; Ruff, CT; Weitz, JI; Wiviott, SD	1
Chang, C; Hou In Chou, O; Iltaf Satti, D; Ka Chung Wai, A; Lee, S; Liu, T; Liu, X; Roever, L; Tai Loy Lee, T; Tak Wong, W; Tse, G; Zhang, Q; Zhou, J	1
Antman, EM; Berger, D; Braunwald, E; Chen, C; Eisen, A; Gencer, B; Giugliano, RP; Grip, LT; Lanz, H; Murphy, SA; Nordio, F; Ruff, CT	1
Haraguchi, Y; Inoue, M; Minami, K; Naito, S; Nakamura, K; Sasaki, T; Yoshimura, S	1
Colivicchi, F	1
Chen, M; Cui, C; Huang, J; Jiang, Q; Li, M; Lin, Y; Miao, W; Shi, J; Zheng, B; Zhu, Y	1
Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Morishima, Y; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M	1
Cho, MS; Cho, YR; Choi, EK; Hwang, J; Hwang, KW; Jin, ES; Kang, DY; Kim, KH; Kim, PJ; Kim, YR; Kwon, CH; Lee, CH; Lee, JH; Nam, GB; Oh, YS; Park, DW; Park, GM; Park, HW; Park, KH; Park, KM; Yoo, KD	1
Hudaib, AR	1
Dangas, GD; Unverdorben, M; Van Mieghem, NM	1
Akao, M; Amino, M; Fukuzawa, M; Funada, J; Hayashi, T; Nakamura, A; Okumura, K; Shimizu, W; Watanabe, S; Yamashita, T; Yoshida, T	1
Fang, L; Kawanishi, H; Murohara, T; Ogawa, H; Ohashi, K; Otaka, N; Ouchi, N; Ozaki, Y; Takahara, K; Takefuji, M; Takikawa, T; Tatsumi, M	1
Alioğlu, E; De Caterina, R; Diker, E; Mavioğlu, Z; Önsel Türk, U; Özpelit, E	1
Akao, M; Fukuzawa, M; Hayashi, T; Imamura, Y; Kuroda, M; Lip, GYH; Nose, T; Ogimoto, A; Okumura, K; Tamiya, E; Taura, J; Yamashita, T	1
Ali, B; Ali, T; Bang, J; Choi, DJ; Choi, S; Hussain, M; Kim, HL; Kim, IC; Kim, IJ; Kim, M; Lee, JH; Lee, S; Park, SJ; Park, SM	1
Bakhai, A; De Caterina, R; Diemberger, I; Fumagalli, S; Gordillo de Souza, JA; Kirchhof, P; Manu, MC; Mazzone, AM; Pecen, L; Reimitz, PE	1
Beyer-Westendorf, J; Fache, K; Köhler, C; Marten, S; Naue, C; Spindler, M; Stannek, L; Tittl, L	1
Akao, M; Akashi, S; Akishita, M; Hayashi, T; Ikeno, E; Manita, M; Oguri, M; Okumura, K; Taura, J; Watanabe, S; Yamashita, T	1
Akao, M; Betsuyaku, T; Hayashi, T; Hirabayashi, K; Imamura, Y; Mikami, T; Okawa, K; Okumura, K; Tanizawa, K; Watanabe, S; Yamashita, T	1
Phizackerley, D	1
Cohen, AA; De Caterina, R; de Groot, JR; Ezekowitz, MD; Goette, A; Heidbuchel, H; Jin, J; Le Heuzey, JY; Lip, GYH; Melino, M; Merino, JL; Merkely, B; Themistoclakis, S; Winters, SM	1
Albendín Iglesias, H; Arregui Montoya, F; Bailén Lorenzo, JL; Caro Martínez, C; Cerezo Manchado, JJ; Elvira Ruiz, G; Flores Blanco, PJ; García Alberola, A; Lova Navarro, A; Manzano-Fernández, S; Pascual Figal, DA	1
Angiolillo, DJ; Capodanno, D	1
Batushkin, V; Campo, G; Eckardt, L; Gargiulo, G; Goette, A; Laeis, P; Lewalter, T; Lysak, Z; Milewski, K; Reimitz, PE; Smolnik, R; Tijssen, J; Vakaliuk, I; Valgimigli, M; Vranckx, P; Zierhut, W	1
Kimura, T; Matsumoto, T; Mukai, Y; Okumura, K; Origasa, H; Takahashi, N; Yamaguchi, K	1
Fernández-Ruiz, I	1
Arita, T; Morishima, Y; Otsuka, T; Suzuki, S; Takita, A; Yagi, N; Yamashita, T	2
Antman, EM; Bergmark, BA; Braunwald, E; Giugliano, RP; Kamphuisen, PW; Kuder, JF; Lanz, HJ; Mercuri, MF; Nordio, F; Ruff, CT; Wiviott, SD	1
Beauchesne, LM; Bouma, BJ; Khairy, P; Macle, L; Mongeon, FP; Mulder, BJM; Schwerzmann, M	1
Agnelli, G; Chen, C; Chiu, KM; Choi, WI; Cohen, A; De Caterina, R; Kaburagi, J; Kim, YH; Kirchhof, P; Koretsune, Y; Laeis, P; Nakamura, M; Rauer, H; Reimitz, PE; Thee, U; Unverdorben, M; Wang, CC; Yamashita, T	1
Bae, HJ; Cho, YK; Choi, SW; Han, S; Hur, SH; Hwang, J; Jun, SW; Kim, H; Kim, IC; Lee, CH; Lee, SH; Nam, CW; Park, HS; Yoon, HJ	1
Eschler, CM; Exadaktylos, AK; Funk, GC; Lindner, G; Maier, V; Walter, P; Woitok, BK	1
Antman, EM; Corbalan, R; Duris, T; Giugliano, RP; Juul-Möller, S; Kerschnitzki, M; Nicolau, AM; Nicolau, JC; Nordio, F; Ruff, CT; Trevisan, M; Voitk, J; Zierhut, W	1
Pastori, D; Pignatelli, P; Violi, F	1
Higashiya, S; Hina, K; Hirohata, S; Kamikawa, S; Kawamura, H; Kusachi, S; Murakami, M; Murakami, T; Yamaji, H	2
Larsen, TB; Lip, GYH; Nielsen, PB; Skjøth, F; Søgaard, M	1
Bhat, Y; Dixit, A; Mistri, A; Patel, B; Quoraishi, SH; Uprichard, J	1
Al-Saady, N; Cohen, A; Goette, A; Goudev, A; Hjortshøj, SP; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Winters, SM	1
Drabik, L; Potpara, T; Undas, A	1
Chaiyakunapruk, N; Dilokthornsakul, P; Hollingworth, W; Jahan, NK; Kongpakwattana, K; Lai, NM; Nathisuwan, S; Ng, SS	1
Aimo, A; De Caterina, R; Petricciuolo, S	1
Goto, E; Horinaka, S; Ishimitsu, T; Kato, T	1
Antman, EM; Braunwald, E; Giugliano, RP; Goudev, A; Grosso, MA; Lanz, HJ; Morais, J; Ostojic, MC; Park, JG; Plitt, A; Ruff, CT	1
Attena, E; De Caterina, R; Di Pasquale, G; Diemberger, I; Riva, L; Sangiuolo, R	1
Zidek, W	1
De Caterina, R; Goette, A; Huber, K; Jin, J; Kozieł, M; Lip, GYH; Melino, M; Merino, JL	1
Gremmel, T; Huber, K	1
De Caterina, R; Limbruno, U	1
Auer, J; Berent, R; Gurtner, F	1
Basili, S; Proietti, M; Romiti, GF	1
Gurbel, PA; Jeong, YH; Kim, YL; Tantry, U	1
Atripaldi, L; D'Onofrio, A; Di Micco, P; Giannetti, L; Golino, P; Laezza, N; Nigro, G; Rago, A; Russo, V	1
Ivankova, J; Mokan, M; Nehaj, F; Sokol, J; Stasko, J	1
De Caterina, R; Goette, A; Heidbuchel, H; Huber, K; Jin, J; Lip, GYH; Merino, JL	1
Arita, T; Kiyosawa, N; Morishima, Y; Otsuka, T; Suzuki, S; Watanabe, K; Yagi, N; Yamashita, T	1
Ho, KH; Leng, G; van Hove, M	1
Acar, RD; Akgün, T; Camm, AJ; Emren, V; Kanat, S; Karacağlar, E; Kepez, A; Kul, Ş; Özel, E; Şimşek, E; Tülüce, K; Türk, UÖ; Yakar Tülüce, S	1
Liu, X; Xu, ZX; Yu, P; Yuan, P; Zhu, WG	1
Ajioka, M; Asano, H; Ishii, H; Kambara, T; Murohara, T; Nakashima, Y; Osanai, H; Sakaguchi, T; Tanaka, A; Tobe, A	1
Beyer-Westendorf, I; Beyer-Westendorf, J; Bornhäuser, M; Festerling, E; Hänsel, U; Marten, S; Mizera, H; Naue, C; Reitter, A; Schreier, T; Spindler, M; Tittl, L	1
Jenkins, A; Katada, J; Kohsaka, S; Li, B; Mardekian, J; Saito, K; Terayama, Y	1
Bauersachs, J; Berliner, D; Flierl, U; Schäfer, A	1
Kobayashi, H; Nomoto, N; Okoshi, Y; Seki, Y; Sone, H; Uemura, S	1
Chen, C; Colonna, P; Laeis, P; Santamaria, A; Saxena, M; Unverdorben, M; Vanassche, T; von Heymann, C; Wilkins, R; Wolpert, D	1
Birschmann, I; Bombach, P; Ebner, M; Härtig, F; Hörber, S; Kuhn, J; Mengel, A; Peter, A; Poli, S; Sonnleitner, M; Spencer, C; Stefanou, MI; Ziemann, U	1
Ameri, P; De Caterina, R; Di Pasquale, G; Riva, L; Toma, M	1
Huang, M; Liu, X; Ma, J; Ye, C; Zeng, C; Zeng, J	1
Chen, HB; Li, YH; Xiu, J; Yu, TH	1
Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Manu, MC; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W	1
Eckardt, L; Goette, A; Laeis, P; Lewalter, T; Marin, F; Reimitz, PE; Schiele, F; Smolnik, R; Tijssen, J; Unikas, R; Valgimigli, M; Vranckx, P; Zierhut, W	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Akao, M; Akashi, S; Akishita, M; Eshima, K; Fukuzawa, M; Hayashi, T; Kawata, M; Lip, GYH; Okazaki, O; Okumura, K; Tanizawa, K; Yamashita, T; Yoshida, T	1
Robson, A	1
Goya, M; Hirao, K; Kawabata, M; Maeda, S; Sasano, T; Takahashi, Y; Yagishita, A	1
Choe, WS; Choi, EK; Han, KD; Jung, JH; Kwon, S; Lee, E; Lee, SR; Lip, GYH; Oh, S	1
Attena, E; Golino, P; Nigro, G; Papa, AA; Parisi, V; Rago, A; Russo, V	1
Kawano, Y; Tamura, A; Yamamoto, E	1
Aucella, F; Barcellona, D; Brunori, G; Forneris, G; Genovesi, SC; Grandone, E; Gresele, P; Marietta, M; Poli, D; Testa, S; Tripodi, A	1
Haas, S; Patti, G	1
Liuzzo, G; Patrono, C	1
Fanaroff, AC; Lopes, RD	1
Cho, YS; Jang, BM; Kim, W; Lee, KE; Lee, MK; Lee, OS; Min, KH	1
Antman, EM; Braunwald, E; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Vilain, K	1
Yavelov, IS	1
Costa, FM; Hemels, MEW	1
Monteiro, P	1
Kamata, K; Kitazumi, Y; Osaka, S; Sezai, A; Suzuki, K; Tanaka, M; Taoka, M	1
Camm, AJ; Cappato, R; Diener, HC; Heidbüchel, H; Hohnloser, SH; Kautzner, J; Lanz, HJ; Mont, L; Morillo, CA; Rauer, H; Reimitz, PE; Smolnik, R	1
Chen, C; Colonna, P; Jin, J; Laeis, P; Santamaria, A; Saxena, M; Unverdorben, M; Vanassche, T; von Heymann, C; Wilkins, R	1
Clegg, A; Gale, CP; Hall, M; Kunadian, V; Rockwood, K; Searle, SD; Todd, O; Wilkinson, C; Wu, J	1
Avorn, J; Gagne, JJ; Kesselheim, AS; Rome, BN	1
Steinberg, DI	1
Blankoff, I; Casado Arroyo, R; Catez, E; Cools, F; Crijns, HJGM; de Asmundis, C; De Caterina, R; de Groot, JR; de Pauw, M; de Veer, A; de Vries, TAC; Hemels, MEW; Kirchhof, P; Lancellotti, P; Mairesse, GH; Vanacker, P; Vanassche, T; Yperzeele, L	1
Antman, EM; Braunwald, E; Giugliano, RP; Lanz, HJ; Nelson, SE; Norden, AD; Park, JG; Rost, NS; Ruff, CT; Silverman, S; Singhal, AB	1
Holzgreve, H	1
Colonna, P; Fazio, G; Fischetti, A; Mannarini, A; Mazzetti, M; Squizzato, A	1
Liang, X; Lin, Z; Liu, M; Xie, W	1
Shrikant Kulkarni, N	1
Steurer, J	1
Antman, EM; Braunwald, E; Connolly, S; Giugliano, RP; Murphy, SA; Park, JG; Ruff, CT; Steffel, J; Yin, O	1
Oh, HJ; Park, BJ; Ryu, KH; Yoon, BH	1
Chao, TF; Chen, C; De Caterina, R; Hong, KS; Kirchhof, P; Lee, BC; Reimitz, PE; Unverdorben, M; Wang, CC	1
Akashi, YJ; Ako, J; Doi, S; Inomata, T; Ishida, M; Kida, K; Kimura, T; Matsumoto, N; Nabeta, T; Ohta, Y; Shiono, T; Suzuki, N; Takita, A; Tsukahara, M; Yamaguchi, K	1
Alexandris-Souphis, T; Ali, MA; Barnes, GD; Decamillo, D; Errickson, J; Froehlich, JB; Haymart, B; Kaatz, S; Kline-Rogers, E; Kong, X; Kozlowski, JH; Krol, GD; Li, Y; Schaefer, JK; Shankar, SR; Sood, SL	1
Cuccia, C; Enea, I; Fresco, C; Paciaroni, M; Patti, G; Pecora, D; Rocca, B; Rubboli, A	1
Bradley, SM; Gosch, KL; Hess, PL; Jani, SM; Maddox, TM; Michael Ho, P; Varosy, PD; Virani, SS	1
Drabik, L; Undas, A	1
Grove, EL; Larsen, TB; Lip, GYH; Nielsen, PB; Ording, AG; Skjøth, F; Søgaard, M	1
Jensen, M; Lip, GY; Nielsen, PB; Ording, AG; Søgaard, M	1
Kimura, T; Mukai, Y; Okumura, K; Origasa, H; Shinohara, T; Takahashi, N; Takita, A; Yamaguchi, K	1
Antman, EM; Berg, DD; Braunwald, E; Giugliano, RP; Im, K; Jarolim, P; Morrow, DA; Ruff, CT; Rutman, H; Tang, M	1
Ajmal, M; Lassar, T; Pecci, C; Srinivasan, S	1
Anderson, R; Baber, U; Boersma, E; Capranzano, P; Chen, C; Dangas, GD; Duggal, A; Hambrecht, R; Hayashida, K; Hengstenberg, C; Jin, J; Kim, HS; Laeis, P; Lang, I; Lanz, H; López-Otero, D; Mehran, R; Meincke, F; Möllmann, H; Moreno, R; Nombela-Franco, L; Nordbeck, P; Ohlmann, P; Pilgrim, T; Rodés-Cabau, J; Saito, S; Shawl, F; Thiele, H; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P; Watanabe, Y; Yamamoto, M; Zamorano, JL	1
Connolly, SJ; Eikelboom, JW; Hirsh, J; Quinlan, DJ; Weitz, JI	1
Di Pasquale, G; Riva, L	2
Barbera, V; Bellasi, A; Campana, C; Cozzolino, M; De Pascalis, A; Di Iorio, B; Di Lullo, L; Galliani, M; Ronco, C; Russo, D; Russo, L; Santoboni, F; Vitaliano, E	1
Collins, R; Gil, VM; Hanon, O; Hardt, R; Hoffmeister, M; Monteiro, P; Quinn, TJ; Ropers, D; Sergi, G; Verheugt, FWA; Wehling, M	1
Burnett, AE; Dobesh, PP; Fanikos, J; Mahan, CE	1
Abugattas de Torres, JP; Brugada, P; Chierchia, GB; Choudhury, R; Coutino-Moreno, HE; de Asmundis, C; De Regibus, V; Iacopino, S; Longobardi, M; Mugnai, G; Storti, C; Stroker, E; Takarada, K	1
Antman, EM; Giugliano, RP; Hamershock, RA; Lanz, HJ; Mercuri, MF; Murphy, SA; Roy, D; Ruff, CT; Senior, R; Steffel, J	1
Ashaye, A; Deitelzweig, S; Farmer, C; Hamilton, M; Horblyuk, R; Li, X; Luo, X; Vo, L	1
Cohen, DJ; Giugliano, RP; Hsu, WH; Hui Tan, EC; Li, H; Magnuson, EA; Vilain, KA; Wang, K; Yang, MC	1
Hu, SJ; Wu, T; Xu, WW	1
Casson, RJ; Chan, W; Sanders, P; Selva, D; Sun, MT; Wong, CX; Wood, MK	1
Jolobe, OM	1
Byström, B; Norrving, B; Oldgren, J; Renlund, H; Själander, A; Sjögren, V; Svensson, PJ	1
Jolobe, OMP	1
Alonso, A; Norby, FL	1
Blank, BF; Calvert, M; Camm, AJ; Chlouverakis, G; Diener, HC; Goette, A; Huening, A; Kirchhof, P; Lip, GYH; Simantirakis, E; Vardas, P	1
Kabra, R; Oliphant, CS; Owens, RE	1
Fogerty, AE; Oertel, LB	1
Goette, A; Hammwöhner, M	1
Antman, EM; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Wang, K	1
Bansal, VK; Choi, MJ; Herzog, CA; Jaar, BG; Kramer, H; Mehta, R; Rocco, MV; Sarnak, MJ	1
Basto, AN; Gibson, CM; Howard, ML	1
Kanai, Y; Matsuda, H; Mitaki, S; Oguro, H; Onoda, K; Tahara, N; Takayoshi, H; Yamaguchi, S	1
Fukuhara, S; Fukuma, S; Furukawa, TA; Goto, Y; Kimachi, K; Kimachi, M	1
Beer, TM; Daughety, MM; DeLoughery, TG; Olson, SR; Shatzel, JJ	1
Al-Saady, N; Banach, M; Ezekowitz, MD; Goette, A; Lip, GYH	1
Grove, EL; Hellfritzsch, M; Pottegård, A	1
Abe, K; Akao, M; Akishita, M; Fukuzawa, M; Lip, GYH; Okumura, K; Tanizawa, K; Yamashita, T	1
Ammar-Busch, S; Bourier, F; Brkic, A; Brooks, S; Deisenhofer, I; Dillier, R; Grebmer, C; Hessling, G; Kaess, B; Koch-Büttner, K; Kolb, C; Kornmayer, M; Kottmaier, M; Lengauer, S; Lennerz, C; Pausch, H; Reents, T; Rousseva, E; Semmler, V; Telishevska, M	1
Franco Moreno, AI; García Navarro, MJ; Martín Díaz, RM	1
Gil, M; Webster, E	1
Antman, EM; Braunwald, E; Cavallari, I; Deenadayalu, N; Giugliano, RP; Lanz, H; Mercuri, MF; Nordio, F; Ruff, CT; Rutman, H; Shi, M	1
Eckardt, L; Goette, A; Lanz, HJ; Lewalter, T; Reimitz, PE; Smolnik, R; Tijssen, JG; Valgimigli, M; Vranckx, P; Zierhut, W	1
Battistella, M; Cameron, K; Farrell, A; Feldberg, J; Ma, J; Patel, P; Sivarajahkumar, S	1
Csanádi, Z; Szegedi, A	1
Aguinaco, MR; Bustins, A; Campoy, D; Canals, T; Cerdá, M; Constans, M; Ene, G; Gabilondo, M; Jiménez, C; Johansson, E; Las Heras, G; López, M; Marzo, C; Mateo, J; Moya, Á; Oliver, A; Olivera, P; Perea, G; Plensa, E; Pons, V; Reverter, JC; Sánchez, E; Santamaría, A; Santos, N; Sorigue, M; Tàssies, D; Varela, A; Vicente, L	1
Beyer-Westendorf, I; Beyer-Westendorf, J; Endig, S; Marten, S; Reitter, A; Tittl, L	1
Camm, J; Cappato, R; Diener, HC; Heidbuchel, H; Hohnloser, SH; Kautzner, J; Lanz, HJ; Mont, L; Morillo, CA; Smolnik, R; Yin, OQP	1
Oung, AB	1
Dülgeroglu, J; Schmidt, D	1
Antman, EM; Braunwald, E; Douketis, JD; Giugliano, RP; Grip, LT; Mercuri, MF; Murphy, SA; Ruff, CT; Weitz, JI	1
Hernandez, I; Hospodar, AR; Smith, KJ; Zhang, Y	1
Aisenberg, J; Antman, EM; Braunwald, E; Chatterjee-Murphy, P; Choi, Y; Friedman Flack, K; Giugliano, RP; Mercuri, MF; Nordio, F; Ruff, CT; Weitz, JI	1
Facchinetti, R; Fantin, F; Ferrari, E; Masciocchi, E; Mazzali, G; Nori, N; Rossi, AP; Sant, S; Zamboni, M; Zoico, E	1
Banach, M; Covic, A; Lopatowska, P; Malyszko, J; Mlodawska, E; Sobkowicz, B; Tomaszuk-Kazberuk, A	1
Mohebbi, N	1
Banach, M; Ezekowitz, MD; Goette, A; Hjortshoj, SP; Kwong, WJ; Lip, GYH; Zamoryakhin, D	1
Lane, DA; Proietti, M	1
Chang, CJ; Chen, SA; Chen, YC; Chen, YJ; Cheng, CC; Higa, S; Huang, JH	1
Antman, EM; Blanc, JJ; Braunwald, E; Cappato, R; Giugliano, RP; Lanz, H; Mercuri, MF; Nordio, F; Ruff, CT; Wiviott, SD; Zelniker, TA	1
Colonna, P; Matsushita, Y; Santamaria, A; Unverdorben, M; von Heymann, C	1
Choi, EK; Han, KD; Jung, JH; Lee, SR; Lip, GYH; Oh, S	2
Goto, S	1
Aizawa, Y; Fujita, S; Fuse, K; Ikeda, Y; Kitazawa, H; Okabe, M; Sato, T; Takahashi, M	1
Baber, U; Boersma, E; Chen, C; Dangas, GD; Hengstenberg, C; Mehran, R; Saito, S; Shi, M; Unverdorben, M; Valgimigli, M; Van Mieghem, NM; Veltkamp, R; Vranckx, P	1
Endo, S; Kishi, H; Kogiku, M; Noda, M; Notsu, Y; Ota, M; Shimizu, M; Takekawa, M; Yamazaki, H; Yamazaki-Nishioka, M	1
Antman, EM; Botero, R; Braunwald, E; Corbalán, R; Garcia-Castillo, A; Giugliano, RP; Grip, LT; Hamershock, RA; Horna, M; López-Sendon, J; Nicolau, JC; Ruff, CT; Sotomora, G	1
Dubner, SJ; Martinenghi, N	1
Maurea, N; Riva, L	1
Antman, EM; Giugliano, RP; Ruff, CT; Zelniker, TA	1
Lip, GYH	1
Andersen, M; Braunschweig, F; Forslund, T; Hjemdahl, P; Komen, JJ; Mantel-Teeuwisse, AK; von Euler, M; Wettermark, B	1
Jang, E; Joung, B; Kim, D; Kim, JY; Kim, TH; Lee, MH; Lip, GYH; Pak, HN; Uhm, JS; Yang, PS; Yu, HT	1
Antman, EM; Babilonia, NA; Braunwald, E; Duggal, A; Fanola, CL; Giugliano, RP; Jin, J; Kamphuisen, PW; Mercuri, MF; Murphy, SA; Ruff, CT; Sritara, P	1
Aoki, J; Kanamaru, T; Kimura, K; Matsumoto, N; Mishina, M; Nishiyama, Y; Nito, C; Okubo, S; Sakamoto, Y; Sekine, T; Shimoyama, T; Suda, S; Suzuki, K	1
Chang, SH; Chu, PH; Kuo, CF; Tseng, HJ; Wang, CL; Wen, MS; Wu, VC	1
Amano, T; Harada, K; Inden, Y; Kato, M; Mamiya, K; Marui, N; Matsunaga, S; Murohara, T; Nagao, T; Nishikawa, Y; Shinoda, N; Suzuki, H	1
Braunschweig, F; Forslund, T; Hjemdahl, P; Holmström, M; Johnsson, H; von Euler, M; Wallén, H	1
Hu, A; Niu, J; Winkelmayer, WC	1
Pommer, P; Stöllberger, C	1
Dei, A; Grifoni, E; Landini, G; Masotti, L; Moroni, F; Panigada, G; Spolveri, S; Vannucchi, V	1
Antman, EM; Braunwald, E; Giugliano, RP; Hamershock, RA; Lanz, HJ; Mercuri, MF; Murphy, SA; Nieminen, M; Peterson, N; Ruff, CT; Steffel, J	1
Oldgren, J	1
Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W	1
Cowperthwaite, M; Fanale, C; Nadasdy, Z; Ramakrishnan, A; Shpak, M	1
Cipriano, LE; Hachinski, V; Lee, SAW; Ruiz Vargas, E; Sposato, LA	1
Antman, EM; Braunwald, E; Chao, TF; Chen, SA; Giugliano, RP; Hamershock, RA; Mercuri, MF; Ruff, CT	1
Büller, HR; Chiang, CE; Giugliano, RP; Lopes, RD; Patel, MR; Tan, DS; Wang, KL	1
Eikelboom, JW; Steffel, J	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1
Antman, EM; Boriani, G; Braunwald, E; Giugliano, RP; Kuder, JF; Lanz, HJ; Mercuri, MF; Ruff, CT; Rutman, H; Shi, M	1
Cohen, AA; De Caterina, R; Goette, A; Heidbuchel, H; Jin, J; Le Heuzey, JY; Lip, GYH; Melino, M; Merino, JL; Winters, SM	1
Bosch, F; Cerdá, M; Cerezo-Manchado, JJ; Fernández, M; Johansson, E; Martínez, F; Rodríguez, S; Santamaría, A; Varela, A	1
Rubboli, A	1
Amiya, R; Higuchi, Y; Hirata, A; Hirayama, A; Kobayashi, T; Sakata, Y; Sotomi, Y	1
Ahmad, A; Al-Khatib, SM; Blank, M; Coylewright, M; DiBattiste, P; Gersh, BJ; Granger, CB; Healey, JS; Hedrich, O; Hylek, EM; Kline-Rogers, E; Mendys, P; Mirro, MJ; Naccarelli, G; Patel, P; Peterson, ED; Pokorney, SD; Ruff, CT; Rutman, H; Stockbridge, N; Temple, R	1
Cha, MJ; Choi, EK; Joung, B; Kang, KW; Kim, C; Kim, J; Kim, JB; Kim, TH; Lee, JM; Lee, SR; Lee, YS; Park, HW; Park, J; Park, JK; Park, JS; Shim, J; Uhm, JS	1
Burhenne, J; Foerster, KI; Haefeli, WE; Lehmann, ML; Mikus, G; Schaumaeker, M	1
Kataoka, N; Kinoshita, K; Kinugawa, K; Nakatani, Y; Nishida, K; Sakamoto, T; Tsujino, Y; Yamaguchi, Y	1
Barrios, V; Cervantes, CE; Merino, JL	1
Pickett, JD	1
Abozguia, K; Camm, J; Cappato, R; Diener, HC; Grimaldi, M; Heidbüchel, H; Hohnloser, SH; Kautzner, J; Mönninghoff, C; Mont, L; Morillo, CA; Rauer, H; Reimitz, PE; Smolnik, R	1
Anguita, M; Barja de Soroa, P; Lekuona, I; Pérez-Alcántara, F; Rodríguez, JM; Zamorano, JL	1
Anker, SD; Doehner, W; von Haehling, S	1
De Candia, E; De Cristofaro, R; Di Gennaro, L; Lancellotti, S	1
Chan, YH; Chang, SH; Chao, TF; Kuo, CT; Lee, HF; Lip, GYH; See, LC; Tu, HT; Wu, LS; Yeh, YH	1
Akiyoshi, K; Goya, M; Hirao, K; Kawabata, M; Koyama, T; Maeda, S; Sekigawa, M; Takahashi, Y; Yagishita, A; Yamamoto, T	1
Attena, E; D'Onofrio, A; Galasso, G; Mazzone, C; Melillo, E; Nigro, G; Parisi, V; Rago, A; Riegler, L; Rotunno, R; Russo, V	1
Granger, CB; Pokorney, SD	2
Cho, EJ; Cho, YS; Jang, BM; Koo Lee, M; Lee, OS; Rhie, SJ; Shin, EJ; Suh, SY	1
Choi, EK; Lee, SR	1
Bakhai, A; de Asmundis, C; De Caterina, R; de Groot, JR; Deharo, JC; Kelly, P; Kerschnitzki, M; Kirchhof, P; Laeis, P; Levy, P; López-de-Sá, E; Monteiro, P; Reimitz, PE; Steffel, J; Waltenberger, J; Weiss, TW; Zierhut, W	1
Chen, H; Deng, Y; Li, S; Tong, Y; Zou, L	1
Bergfeldt, L; Blomström-Lundqvist, C; Boriani, G; Botto, GL; Camm, AJ; Capucci, A; Goette, A; Hohnloser, SH; Israel, CW; Lozano, IF; Merino, JL	1
Daida, H; Fujimoto, S; Hagiwara, N; Iguchi, Y; Iwasaki, YK; Kaburagi, J; Kanamaru, T; Kimura, K; Kimura, T; Kitagawa, K; Kusano, K; Matsumoto, T; Miyamoto, S; Nishiyama, Y; Okumura, K; Otsuka, T; Sakamoto, Y; Shimizu, W; Toyoda, K; Yamamoto, T	1
Antman, EM; Bergmark, BA; Braunwald, E; Chung, N; Giugliano, RP; Lanz, HJ; Park, S; Ruff, CT; Shi, M	1
Badimón, JJ; Briongos Figuero, S; García Santos-Gallego, C	1
Lopes, RD; Newby, LK; Truffa, AA	1
Antman, EM; Betcher, J; Braunwald, E; Ezekowitz, MD; Giugliano, RP; Grip, LT; Halperin, JL; Hanyok, JJ; Koretsune, Y; Mercuri, M; Murphy, SA; Patel, I; Patel, SP; Ruda, M; Ruff, CT; Ruzyllo, W; Shi, M; Špinar, J; Waldo, AL; Weitz, JI; Wiviott, SD	1
Antman, EM; Braunwald, E; Deenadayalu, N; Giugliano, RP; Grip, LT; Gupta, DK; Hoffman, E; Mercuri, M; Mitrovic, V; Patel, I; Ruff, CT; Shah, AM; Shi, M; Solomon, SD	1
Mitka, M	1
Giugliano, RP; Gonzalez-Quesada, CJ	1
Chan, NC; Eikelboom, JW; Ginsberg, JS; Hirsh, J; Lauw, MN; Paikin, JS	1
Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	1
Giugliano, RP; Plitt, A	3
Davidson, N; Galloway, SW; Lai, A; Thachil, J	1
Bentzen, BH; Christ, T; Diness, JG; Grunnet, M; Jespersen, T; Kappert, U; Matschke, K; Poulet, C; Ravens, U; Skibsbye, L; Wettwer, E; Yuan, L	1
Hürlimann, D; Noll, G; Noll, S	1
Corelli, K; Ezekowitz, MD; Ghosh, P; Spahr, J	1
Prabhakaran, S; Veltkamp, R	1
Antman, EM; Betcher, JM; Braunwald, E; Dave, J; Deenadayalu, N; Duggal, A; Giugliano, RP; Grip, LT; Lowe, C; Mercuri, M; Murphy, SA; Rost, NS; Ruff, CT; Shi, M; Silverman, S; Wiviott, SD	1
Liberato, NL; Marchetti, M; Quaglini, S; Rognoni, C	1
Cowell, RP	1
Bounameaux, H; Camm, AJ	2
Mitchell, AR; Page, PL; Thomas, R	1
Bongu, NR; Kocheril, AG; Turagam, MK; Velagapudi, P	1
Antman, EM; Betcher, J; Braunwald, E; Cange, AL; Crompton, AE; Curt, V; Deenadayalu, N; Giugliano, RP; Grip, L; Mercuri, M; Murphy, SA; Ruff, CT	1
Bang, OY; Chung, CS; Kim, GM; Kim, JS; Kim, SJ; Lee, KH; Lee, MJ; Park, YK; Ryoo, S; Yoon, CH	1
Miller, R; Tetsuya, K; Yin, OQ	1
Giugliano, RP	1
Lane, DA; Lip, GY; Senoo, K	1
Madhusudhana, S; Qasem, A; Strasser, KM	1
Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S	1
Ezekowitz, MD; Kent, AP	1
Baber, U; Mastoris, I; Mehran, R	1
Amin, A; Deitelzweig, S	1
Amin, A; Bruno, A; Lin, J; Lingohr-Smith, M; Trocio, J	1
Arepally, GM; Ortel, TL	1
Traynor, K	1
Antman, EM; Braunwald, E; Cermak, O; Giugliano, RP; Grip, LT; Kania, G; Mercuri, MF; Murphy, SA; O'Donoghue, ML; Ruff, CT; Rutman, H; Shi, M	1
Loffredo, L; Perri, L; Violi, F	1
Patel, MR; Washam, JB	1
Antman, EM; Braunwald, E; Deenadayalu, N; Giugliano, RP; Lee, J; Mega, JL; Mercuri, MF; Murphy, SA; Nordio, F; Ruff, CT; Sabatine, MS; Vandell, AG; Walker, JR	1
Antman, EM; Betcher, J; Braunwald, E; Brown, K; Deenadayalu, N; Giugliano, RP; Jarolim, P; Kuder, JF; Mercuri, M; Morrow, DA; Murphy, SA; Patel, I; Ruff, CT; Shi, M	1
Wu, AH	1
Hogg, K; Weitz, JI; Yeh, CH	1
Huynh, K	1
Harenberg, J; Krejczy, M; Lip, GY; Obermann, K; Wehling, M	1
Armbruster, AL; Minor, C; Tellor, KB	1
Lane, DA; Wood, K	1
Abe, K; Fukuzawa, M; Kimura, T; Koretsune, Y; Yamashita, T; Yasaka, M	1
Al-Saadi, N; Ellenbogen, K; Ezekowitz, M; Goette, A; Jin, J; Lanz, H; Lip, GY; Mercuri, M; Merino, J; Zamoryakhin, D	1
Wright, GE	1
Antman, EM; Atar, D; Braunwald, E; Camm, AJ; Giugliano, RP; Heidbuchel, H; Murphy, SA; Ruff, CT; Steffel, J	1
Ikeda, T	1
Blann, AD; Larsen, TB; Lip, GY; Rasmussen, LH; Skjøth, F	1
Conen, D	1
Barrios, V; Escobar, C	2
Lip, GY; Proietti, M	2
Ge, D; Morrill, AM; Willett, KC	1
Crawford, B; Morimoto, T; Ueda, S; Wada, K	1
Drambarean, B; Hellenbart, E; Lee, J; Nutescu, EA	1
Lau, YC; Lip, GY; Xiong, Q	1
Chen, J; Long, M; Su, C; Wang, L; Zhuang, X	1
Hong, K; Lane, DA; Lau, YC; Lip, GY; Senoo, K; Xiong, Q	1
Hijazi, Z; Oldgren, J	1
McCormack, PL	1
Banerjee, A; Blann, AD; Lane, DA; Lip, GY; Torp-Pedersen, C	1
Antman, EM; Braunwald, E; Geller, BJ; Giugliano, RP; Hanyok, JJ; Jin, J; Mercuri, M; Murphy, SA; Ruff, CT	1
Colonna, P; Rubboli, A	1
Eikelboom, J; Weitz, JI	1
Riess, H	1
Chalkiadaki, C; Dorian, P; Kongnakorn, T; Kuznik, A; Lanitis, T; Lawrence, J; Lip, GY; Liu, X; Phatak, H	1
Azimi, N; Forest, CP; Holden, A	1
Dzeshka, MS; Lip, GY	1
Brekelmans, M; Coppens, M; Middeldorp, S	1
Roca, B; Roca, M	1
Batson, S; Kachroo, S; Lip, GY; Liu, LZ; Liu, X; Mitchell, SA; Phatak, H	1
McBane, RD; Schaefer, JK; Wysokinski, WE	1
Antman, EM; Cohen, DJ; Giugliano, RP; Kwong, WJ; Li, H; Magnuson, EA; Ruff, CT; Vilain, K; Wang, K	1
Eisen, A; Ruff, CT	1
Didier, R; Escarcega, RO; Kiramijyan, S; Koifman, E; Lipinski, MJ; Torguson, R; Waksman, R	1
Cheung, BM; Kumana, CR; Lauder, IJ; Siu, DC; Tse, HF	1
Ajioka, M; Asano, H; Inoue, Y; Ishihama, S; Kanbara, T; Kuwayama, T; Masutomi, T; Nakashima, Y; Osanai, H; Sakai, K; Takahashi, M	1
Antman, EM; Awasty, VR; Braunwald, E; Eisen, A; Giugliano, RP; Gogia, HS; Henderson, DA; Mercuri, MF; Nordio, F; Ruff, CT; Rutman, H	1
Alamneh, EA; Bereznicki, LR; Chalmers, L	1
Abe, K; Chen, SA; Chung, N; Giugliano, RP; Kimura, T; Koretsune, Y; Mercuri, M; Miyazaki, K; Ruff, CT; Shimada, YJ; Yamashita, T; Yang, Y	1
Antman, EM; Braunwald, E; Giugliano, RP; Mercuri, M; Murphy, SA; Nordio, F; Patel, I; Ruff, CT; Shi, M; Xu, H	1
Alcocer, L	1
Kaufner, L; Rosenthal, C; Sander, M; von Heymann, C	1
Jönsson, S; Karlsson, KE; Karlsson, MO; Krekels, EH; Miller, R; Niebecker, R; Ruff, CT; Shimizu, T; Simonsson, US	1
Boehlen, F; Bounameaux, H; Fontana, P; Righini, M; Robert-Ebadi, H	1
Antman, EM; Braunwald, E; Giugliano, RP; Kappelhof, JA; Mercuri, MF; Murphy, SA; Nordio, F; Ruff, CT; Shi, M; Wiviott, SD	1
Coleman, CI; Egri, F; Mearns, ES; Nguyen, E; White, CM	1
De Caterina, R; Ezekowitz, MD; Giugliano, RP; Nordio, F; Peterson, N; Plitt, A	1
Hayes, CJ; Martin, BC; Shah, A; Shewale, A	1
Aoyagi, H; Asano, M; Hirao, K; Kawaguchi, N; Kurabayashi, M; Nakamura, T; Okishige, K; Sasano, T; Shimura, T; Suzuki, H; Yamashita, M; Yamauchi, Y	1
Bereczki, D; Mirolovics, Á; Papp, C; Zsuga, J	1
Antman, EM; Braunwald, E; Giugliano, RP; Jin, J; Kato, ET; Kimura, T; Kiss, RG; Koretsune, Y; Lanz, H; Mercuri, M; Murphy, SA; Nordio, F; Ruff, CT; Yamashita, T	1
Cigarroa, J; Henrikson, CA; Steinberg, JS; Tereshchenko, LG	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Abramson, S; Chan, KE; Giugliano, RP; Jardine, M; Maddux, FW; Patel, MR; Perkovic, V; Piccini, JP; Zhao, S	1
Mizoguchi, T; Yasaka, M	1
Cutler, NR; Goldenberg, NA; Halperin, JL; Hiatt, WR; Kessler, CM; Kittelson, JM; Schulman, S; Spyropoulos, AC; Steg, PG; Turpie, AG	1
Antman, EM; Braunwald, E; Giugliano, RP; Magnani, G; Mercuri, M; Metra, M; Mitrovic, V; Moccetti, T; Murphy, SA; Nordio, F; Ruff, CT; Shi, M	1
Antman, EM; Bohula, EA; Braunwald, E; Giugliano, RP; Kuder, JF; Murphy, SA; Ruff, CT	1
Antman, EM; Braunwald, E; Crompton, AE; Giugliano, RP; Mercuri, MF; Murphy, SA; Nicolau, JC; Norden, AD; Rost, NS; Ruff, CT; Silverman, S; Singhal, AB; SomaRaju, B	1
Antman, EM; Braunwald, E; Corbalán, R; Dalby, A; Dorobantu, M; Eisen, A; Giugliano, RP; Lanz, H; Mercuri, M; Nordio, F; Ruff, CT; Rutman, H; Wiviott, SD	1
Yasumasu, T	1
Yamashita, T	1
Saito, S; Shindo, S; Shirakawa, M; Tsudaka, S; Uchida, K; Yoshimura, S	1
Handa, A; Hurst, KV; O'Callaghan, JM	1
Eikelboom, J; Merli, G	1
DeFelipe, A; Masjuan, J	1
Al-Saady, N; Batushkin, V; de Groot, JR; Ezekowitz, MD; Fernandez, V; Goette, A; Grosso, MA; Jin, J; Kushnir, M; Lip, GY; Melino, M; Mercuri, MF; Merino, JL; Merkely, B; Pelekh, N; Spinar, J; Zamoryakhin, D; Zenin, S	1
Granger, CB; Hawkins, NM; Jhund, PS; McMurray, JJ; O'Meara, E; Petrie, MC; Pfeffer, MA; Pozzi, A; Solomon, SD; Swedberg, K; Virani, S; Yusuf, S	1
Antman, EM; Aylward, P; Braunwald, E; Choi, Y; Giugliano, RP; Mercuri, M; Murphy, SA; Ruff, CT; Steffel, J; White, H; Zamorano, JL	1
Dellegrottaglie, S; Filippatos, G; Giugliano, RP; Lund, LH; Magnani, G; McMurray, J; Perrone-Filardi, P; Rosano, GM; Savarese, G; Trimarco, B	1
Beyer-Westendorf, J; Hauswald-Dörschel, S; Marten, S; Michalski, F; Tittl, L	1
Abildgaard, L; Diness, JG; Grunnet, M; Jespersen, T; Kirchhoff, JE; Sheykhzade, M	1
Barrios, V; Masjuan, J	1
Ansell, J; Fonarow, GC; Gersh, BJ; Go, AS; Hylek, EM; Kowey, PR; Mahaffey, KW; Peterson, ED; Piccini, JP; Pokorney, SD; Shrader, P; Singer, DE; Thomas, L	1
Hernandez, I; Smith, KJ; Zhang, Y	1
Horiuchi, D; Ishida, Y; Itoh, T; Kimura, M; Kinjo, T; Nishizaki, K; Okumura, K; Sasaki, K; Sasaki, S; Shoji, Y; Tomita, H; Tsushima, Y	1
Bramlage, P; Minguet, J; Sims, HM; Smith, KH	1
Aspromonte, N; Colivicchi, F	1
Doukky, R; Jaffer, AK; Moseley, A; Volgman, AS; Williams, KA	1
Blann, AD; Boriani, G; Lip, GY	1
Bhatt, DL; Fonarow, GC; Harding, T; Hernandez, AF; Khan, Y; Peterson, ED; Schwamm, LH; Suter, RE; Xian, Y	1
Guo, L; Hong, Y; Li, S; Wang, P; Zhong, X	1
Kimura, T; Kumakura, T; Shimizu, T; Tachibana, M; Yoshihara, K	1
Antman, EM; Braunwald, E; Fanola, CL; Giugliano, RP; Mercuri, MF; Nordio, F; Ruff, CT; Trevisan, M	1
Antman, EM; Braunwald, E; Crompton, AE; Giugliano, RP; Huikuri, H; Lanz, H; Link, MS; Mercuri, MF; Murphy, SA; Oto, A; Ruff, CT; Scirica, BM	1
Baig, U; David, T; Poulakos, M; Walker, JN	1
Oda, H; Sugiyama, T	1
Ageno, W; Becattini, C; D'Angelo, A; Davì, G; De Cristofaro, R; Dentali, F; Di Minno, G; Falanga, A; Gussoni, G; Masotti, L; Palareti, G; Pignatelli, P; Prisco, D; Santi, RM; Santilli, F; Silingardi, M; Tufano, A; Violi, F	1
Ageno, W; Agnelli, G; Boriani, G; Colonna, P; De Caterina, R; Ghirarduzzi, A; Patti, G; Rossini, R; Rubboli, A; Schinco, P	1
Weitz, JI	2
Antman, E; Carnicelli, AP; De Caterina, R; Giugliano, RP; Halperin, JL; Mercuri, MF; Nordio, F; Renda, G; Ruff, CT; Trevisan, M	1
EncisoSilva, J; Greenberg, B; Schlueter, M; Thomas, I	1
Ay, C; Dieplinger, B; Domanovits, H; Fries, D; Gary, T; Rohla, M; Vosko, MR; Weiss, TW	1
Antman, EM; Braunwald, E; Carnicelli, AP; De Caterina, R; Giugliano, RP; Mercuri, MF; Nordio, F; Renda, G; Ruff, CT; Trevisan, M	1
Coskun, O; Dalkiran, M; Duran, A; Emul, M; Keles, I; Tosun, M; Ugur, M; Yavuz, R	1
Eikelboom, J; O'Donnell, M; Sobieraj-Teague, M	1
Lopes, RD; Mahaffey, KW; Piccini, JP	1
Al-Shahib, B; Diness, JG; Grunnet, M; Hansen, RS; Jespersen, T; Nissen, JD; Sørensen, US	1
Connolly, SJ; Jin, J; Kastrissios, H; Kunitada, S; Mendell, J; Patel, I; Rohatagi, S; Salazar, D; Weitz, JI	1
Morishima, Y; Shibano, T	1
Antman, EM; Bocanegra, T; Braunwald, E; Crugnale, SE; Giugliano, RP; Hanyok, J; McCabe, CH; Mercuri, M; Patel, I; Ruff, CT; Salazar, D; Shi, M	1
Chen, SA; Chung, N; Chung, WS; Jeon, HK; Lai, WT; Lee, TH; Lien, LM; Tse, HF	1
Eikelboom, JW; Eriksson, BI; Quinlan, DJ	1
Giugliano, RP; Partida, RA	1
Nagao, T	1
Antman, EM; Bocanegra, TS; Carrothers, TJ; Dornseif, B; Giugliano, RP; Green, M; Kastrissios, H; Kunitada, S; Mendell, J; Patel, I; Rohatagi, S; Salazar, DE; Shi, M; Song, S; Tachibana, M; Zhou, S	1
Ackerman, U; Churilov, L; Donnan, GA; Gong, SJ; Gunawan, R; Ly, JV; Ma, H; O'Keefe, G; Rowe, CC; Sahathevan, R; Saunder, T; Tochon-Danguy, H; Villemagne, VL; Zavala, JA	1
Bommer, WJ	1
Halperin, JL; Varughese, CJ	1
Inoue, H; Kawai, Y; Koretsune, Y; Matsumoto, M; Ogawa, S; Uchiyama, S; Yamaguchi, T; Yamashita, T; Yasaka, M	1
Lip, GY; Marín, F; Roldán, V	1
Koziński, M; Kubica, A; Kubica, J; Navarese, EP; Obońska, K	1
Martin, EN; Money, SR; Shamoun, FE	1
Finsterer, J; Gatterer, E; Stöllberger, C	1
Guttmann, I; Mozes, A; Scheufler, E; Wilffert, B	1

Reviews

120 review(s) available for thiazoles and Atrial Fibrillation

Article	Year
Non-Vitamin K Antagonist Oral Anticoagulants in Adult Congenital Heart Disease. The Canadian journal of cardiology, 2019, Volume: 35, Issue:12 Topics: Administration, Oral; Adult; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation; Dabigatran; Female; Heart Defects, Congenital; Heart Valve Diseases; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Severity of Illness Index; Sex Factors; Stroke; Survival Analysis; Thiazoles; Vitamin K	2019
Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. Polish archives of internal medicine, 2020, 01-31, Volume: 130, Issue:1 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles	2020
Comparative efficacy and safety of warfarin care bundles and novel oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Scientific reports, 2020, 01-20, Volume: 10, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Care Bundles; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin	2020
[Oral anticoagulation in patients with atrial fibrillation and stage 4 or 5 chronic kidney disease]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:1 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Diabetes Complications; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Hypertension; Male; Middle Aged; Off-Label Use; Prevalence; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Sex Factors; Sleep Apnea, Obstructive; Stroke; Thiazoles; Thromboembolism	2020
MMW Fortschritte der Medizin, 2020, Volume: 162, Issue:4 Topics: Atrial Fibrillation; Blood Pressure; Humans; Hypertension; Pyridines; Thiazoles; Warfarin	2020
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies. Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:4 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Intracranial Hemorrhages; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin	2020
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. Cardiovascular drugs and therapy, 2020, Volume: 34, Issue:4 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Vitamin K; Warfarin	2020
The role of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation: A PRISMA-compliant article. Medicine, 2020, Jul-02, Volume: 99, Issue:27 Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Asia; Asian People; Atrial Fibrillation; Cost of Illness; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Safety; Stroke; Thiazoles; Warfarin	2020
The risk of bleeding and all-cause mortality with edoxaban versus vitamin K antagonists: A meta-analysis of phase III randomized controlled trials. Thrombosis research, 2020, Volume: 194 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Vitamin K	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Non-Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Journal of cardiovascular pharmacology, 2020, 10-14, Volume: 77, Issue:1 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Stroke; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome	2020
[Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin]. Kardiologiia, 2020, Sep-17, Volume: 60, Issue:8 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin	2020
MMW Fortschritte der Medizin, 2021, Volume: 163, Issue:1 Topics: Aged; Atrial Fibrillation; Humans; Patients; Pyridines; Thiazoles	2021
The efficacy and safety of edoxaban versus warfarin in preventing clinical events in atrial fibrillation: A systematic review and meta-analysis. Anatolian journal of cardiology, 2021, Volume: 25, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2021
The risk of gastrointestinal hemorrhage with non-vitamin K antagonist oral anticoagulants: A network meta-analysis. Medicine, 2021, Mar-19, Volume: 100, Issue:11 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Enoxaparin; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Network Meta-Analysis; Observational Studies as Topic; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2021
Edoxaban in cardiovascular disease management: Review. British journal of clinical pharmacology, 2022, Volume: 88, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles	2022
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review. JAMA cardiology, 2017, 05-01, Volume: 2, Issue:5 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Chromatography, High Pressure Liquid; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Partial Thromboplastin Time; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Tandem Mass Spectrometry; Thiazoles; Thrombin Time; Warfarin	2017
[New oral anticoagulants in patients with atrial fibrillation: efficacy and safety data from the real world]. Giornale italiano di cardiologia (2006), 2017, Volume: 18, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome	2017
Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thrombosis research, 2017, Volume: 155 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin	2017
Appropriateness of Oral Anticoagulants for the Long-Term Treatment of Atrial Fibrillation in Older People: Results of an Evidence-Based Review and International Consensus Validation Process (OAC-FORTA 2016). Drugs & aging, 2017, Volume: 34, Issue:7 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Consensus; Dabigatran; Delphi Technique; Europe; Evidence-Based Practice; Female; Humans; Long-Term Care; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Stroke; Thiazoles; Warfarin	2017
Renal Function Considerations for Stroke Prevention in Atrial Fibrillation. The American journal of medicine, 2017, Volume: 130, Issue:9 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pharmaceutical Research; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin	2017
Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies. Current medical research and opinion, 2017, Volume: 33, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk; Rivaroxaban; Thiazoles; Warfarin	2017
Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. Journal of Zhejiang University. Science. B, 2017, Volume: 18, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Bayes Theorem; Clinical Trials as Topic; Dabigatran; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Markov Chains; Middle Aged; Monte Carlo Method; Network Meta-Analysis; Odds Ratio; Pyridines; Randomized Controlled Trials as Topic; Risk; Thiazoles; Warfarin	2017
Risk of Intraocular Bleeding With Novel Oral Anticoagulants Compared With Warfarin: A Systematic Review and Meta-analysis. JAMA ophthalmology, 2017, 08-01, Volume: 135, Issue:8 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Eye Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Assessment; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. Journal of comparative effectiveness research, 2017, Volume: 6, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Epidemiologic Methods; Factor Xa Inhibitors; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2017
Use of direct oral anticoagulants for stroke prevention in elderly patients with nonvalvular atrial fibrillation. Journal of the American Association of Nurse Practitioners, 2017, Volume: 29, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
The safety of edoxaban for treating atrial fibrillation. Expert opinion on drug safety, 2017, Volume: 16, Issue:11 Topics: Administration, Oral; Animals; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Medication Adherence; Pyridines; Stroke; Thiazoles; Thromboembolism	2017
Direct Oral Anticoagulants in Cardioversion: A Review of Current Evidence. The Annals of pharmacotherapy, 2018, Volume: 52, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Electric Countershock; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles	2018
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane database of systematic reviews, 2017, Nov-06, Volume: 11 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
Management of Anticoagulation in Patients With Prostate Cancer Receiving Enzalutamide. Journal of oncology practice, 2017, Volume: 13, Issue:11 Topics: Androgen Receptor Antagonists; Anticoagulants; Atrial Fibrillation; Benzamides; Dabigatran; Drug Interactions; Embolism; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism; Warfarin	2017
Direct oral anticoagulants: An update. Medicina clinica, 2018, 09-14, Volume: 151, Issue:5 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Venous Thromboembolism; Withholding Treatment	2018
Advances in anticoagulation therapy. JAAPA : official journal of the American Academy of Physician Assistants, 2018, Volume: 31, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thrombosis	2018
A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2019, 02-01, Volume: 34, Issue:2 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Embolism; Glomerular Filtration Rate; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2019
[Peri-Interventional Management of Direct Oral Anticoagulants - Balancing Benefits and Risks]. Praxis, 2018, Volume: 107, Issue:9-10 Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Blood Coagulation Factors; Blood Coagulation Tests; Colonoscopy; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Male; Premedication; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thromboembolism	2018
Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants? International urology and nephrology, 2018, Volume: 50, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles	2018
[The Multimorbid Patient: Use of New Oral Anticoagulants in Patients with Chronic Kidney Disease]. Praxis, 2018, Volume: 107, Issue:13 Topics: Anticoagulants; Arterial Occlusive Diseases; Atrial Fibrillation; Comorbidity; Contraindications; Coronary Disease; Dabigatran; Glomerular Filtration Rate; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K	2018
The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: A meta-analysis of randomized trials. European heart journal. Acute cardiovascular care, 2019, Volume: 8, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Case-Control Studies; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Pyridines; Randomized Controlled Trials as Topic; Safety; Stroke; Thiazoles; Treatment Outcome; Warfarin	2019
The safety of NOACs in atrial fibrillation patient subgroups: A narrative review. International journal of clinical practice, 2019, Volume: 73, Issue:2 Topics: Administration, Oral; Age Factors; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin	2019
[Improved stroke prevention in atrial fibrillation: the Stockholm experience of the introduction of NOACs]. Lakartidningen, 2018, 10-26, Volume: 115 Topics: Aged, 80 and over; Antithrombins; Atrial Fibrillation; Dabigatran; Humans; Ischemic Attack, Transient; Observational Studies as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Sweden; Thiazoles; Warfarin	2018
Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation. Seminars in nephrology, 2018, Volume: 38, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Thiazoles; Thromboembolism; Warfarin	2018
Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin	2019
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019
Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert review of cardiovascular therapy, 2019, Volume: 17, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Thromboembolism; Warfarin	2019
Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients With Cancer and Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of the American Heart Association, 2019, 07-16, Volume: 8, Issue:14 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Embolism; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Intracranial Hemorrhages; Neoplasms; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2019
Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, 12-01, Volume: 21, Issue:12 Topics: Anti-Arrhythmia Agents; Antithrombins; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Dabigatran; Digoxin; Dronedarone; Drug Interactions; Factor Xa Inhibitors; Heart Failure; Hospitalization; Humans; Mortality; Pyridines; Randomized Controlled Trials as Topic; Thiazoles	2019
[Improvements in oral anticoagulant therapy for atrial fibrillation]. Medicina clinica, 2013, Dec-07, Volume: 141, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Benzylamines; beta-Alanine; Dabigatran; Embolism; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome; Warfarin	2013
Alternatives to warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a look back at the state of the field in 2012. Postgraduate medicine, 2013, Volume: 125, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2013
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Data Interpretation, Statistical; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Treatment Outcome	2014
Edoxaban: Review of pharmacology and key phase I to III clinical trials. Journal of cardiovascular pharmacology and therapeutics, 2014, Volume: 19, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Venous Thrombosis; Warfarin	2014
Stroke prevention in atrial fibrillation: established oral anticoagulants versus novel anticoagulants-translating clinical trial data into practice. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2014, Volume: 40, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Translational Research, Biomedical; Treatment Outcome	2014
Direct oral anticoagulants: integration into clinical practice. Postgraduate medical journal, 2014, Volume: 90, Issue:1067 Topics: Acute Kidney Injury; Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Drug Administration Schedule; Hemorrhage; Humans; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome	2014
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs, 2014, Volume: 74, Issue:11 Topics: Administration, Oral; Animals; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism	2014
Atrial fibrillation - new frontiers in anticoagulation. Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2014
Novel anticoagulants vs warfarin for stroke prevention in atrial fibrillation. Cardiovascular & hematological disorders drug targets, 2014, Volume: 14, Issue:1 Topics: Animals; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Discovery; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Oral anticoagulants for stroke prevention in atrial fibrillation. Current problems in cardiology, 2014, Volume: 39, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Administration Schedule; Drug Therapy, Combination; Humans; Morpholines; Patient Preference; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2014
Target-specific oral anticoagulants: practice issues for the clinician. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Drug Interactions; Humans; Medication Adherence; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2014
Switching between oral anticoagulants. Hospital practice (1995), 2014, Volume: 42, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; United States; Warfarin	2014
Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation. International journal of clinical pharmacology and therapeutics, 2015, Volume: 53, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Coagulation; Dabigatran; Humans; Morpholines; Orthopedic Procedures; Patient Safety; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Thiophenes; Treatment Outcome; Venous Thromboembolism	2015
Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nature reviews. Cardiology, 2014, Volume: 11, Issue:12 Topics: Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemia; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism	2014
Target-specific oral anticoagulants and the hospitalist. Hospital practice (1995), 2015, Volume: 43, Issue:1 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Hospitalists; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis; Warfarin	2015
Changing practice of anticoagulation: will target-specific anticoagulants replace warfarin? Annual review of medicine, 2015, Volume: 66 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2015
Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: A meta-analysis of interventional trials. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2015, Volume: 47, Issue:5 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Risk Factors; Rivaroxaban; Thiazoles; Warfarin	2015
Overview of the new oral anticoagulants: opportunities and challenges. Arteriosclerosis, thrombosis, and vascular biology, 2015, Volume: 35, Issue:5 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dabigatran; Dose-Response Relationship, Drug; Drug Administration Schedule; Factor Xa Inhibitors; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sensitivity and Specificity; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin	2015
Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy. Nature reviews. Cardiology, 2015, Volume: 12, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Warfarin	2015
Edoxaban, a Novel Oral Factor Xa Inhibitor. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:7 Topics: Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Venous Thromboembolism	2015
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thrombosis and haemostasis, 2015, Volume: 114, Issue:2 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Embolism; Factor Xa Inhibitors; Humans; Mortality; Numbers Needed To Treat; Observational Studies as Topic; Platelet Aggregation Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Assessment; Stroke; Thiazoles; Thrombophilia; Ticlopidine; Vitamin K	2015
Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:7 Topics: Administration, Oral; Arthroplasty, Replacement, Hip; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism	2015
Antidotes to non-vitamin K oral anticoagulants: necessary or not? Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:11 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Dosing of Target-Specific Oral Anticoagulants in Special Populations. The Annals of pharmacotherapy, 2015, Volume: 49, Issue:9 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Humans; Kidney Diseases; Liver Diseases; Obesity; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Venous Thromboembolism	2015
Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. Journal of cardiology, 2015, Volume: 66, Issue:6 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Dabigatran; Hemorrhage; Humans; Myocardial Infarction; Odds Ratio; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K	2015
Apixaban versus edoxaban for stroke prevention in nonvalvular atrial fibrillation. Journal of comparative effectiveness research, 2015, Volume: 4, Issue:4 Topics: Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles	2015
Efficacy and Safety of Edoxaban in Nonvalvular Atrial Fibrillation: A Meta-analysis of Randomized Controlled Trials. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2015, Volume: 24, Issue:12 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Treatment Outcome; Warfarin	2015
Non-vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta-analysis of randomized trials. European journal of heart failure, 2015, Volume: 17, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Heart Failure; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk Adjustment; Stroke; Thiazoles; Treatment Outcome; Warfarin	2015
[Large studies of NOAC shows good and safe stroke protection]. Lakartidningen, 2015, Sep-08, Volume: 112 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin	2015
Edoxaban: a review in nonvalvular atrial fibrillation. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2015, Volume: 15, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Warfarin	2015
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation. Thrombosis and haemostasis, 2016, Volume: 115, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Dabigatran; Embolism; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
[Treatment of bleeding complications due to oral anticoagulant drugs]. Laryngo- rhino- otologie, 2015, Volume: 94, Issue:10 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thromboembolism; Vitamin K	2015
New oral anticoagulants for patients with nonvalvular atrial fibrillation. JAAPA : official journal of the American Academy of Physician Assistants, 2015, Volume: 28, Issue:11 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles	2015
Edoxaban for reducing the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:17 Topics: Atrial Fibrillation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Risk; Stroke; Thiazoles; Thromboembolism; Vitamin K; Warfarin	2015
Direct factor Xa inhibitor edoxaban: from bench to clinical practice. Expert review of hematology, 2015, Volume: 8, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism	2015
The new oral anticoagulants: Reasonable alternatives to warfarin. Cleveland Clinic journal of medicine, 2015, Volume: 82, Issue:12 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thrombosis	2015
Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. International journal of cardiology, 2016, Feb-01, Volume: 204 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Thiazoles; Vitamin K	2016
How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Annals of hematology, 2016, Volume: 95, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; beta-Alanine; Clinical Decision-Making; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin	2016
Edoxaban in patients with atrial fibrillation. Therapeutic advances in cardiovascular disease, 2017, Volume: 11, Issue:3 Topics: Administration, Oral; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles	2017
Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation: A network meta-analysis. International journal of cardiology, 2016, Feb-15, Volume: 205 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Defibrillators, Implantable; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Thiazoles; Warfarin	2016
Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights. Cardiovascular therapeutics, 2016, Volume: 34, Issue:2 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
Suboptimal Use of Oral Anticoagulants in Atrial Fibrillation: Has the Introduction of Direct Oral Anticoagulants Improved Prescribing Practices? American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Blood Coagulation Factors; Dabigatran; Dose-Response Relationship, Drug; Evidence-Based Medicine; Factor Xa Inhibitors; Humans; Medication Errors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Administration Schedule; Drugs, Investigational; Evidence-Based Medicine; Humans; Mexico; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Vitamin K	2016
Management of direct oral anticoagulants-associated bleeding in the trauma patient. Current opinion in anaesthesiology, 2016, Volume: 29, Issue:2 Topics: Administration, Oral; Antifibrinolytic Agents; Antithrombins; Atrial Fibrillation; Clinical Protocols; Dabigatran; Factor Xa Inhibitors; Hemorrhage; Humans; Plasma; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; United States; Wounds and Injuries	2016
Direct oral anticoagulants: a guide for daily practice. Swiss medical weekly, 2016, Volume: 146 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recurrence; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2016
Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vascular health and risk management, 2016, Volume: 12 Topics: Administration, Oral; Animals; Anticoagulants; Antidotes; Atrial Fibrillation; Blood Coagulation; Coagulants; Hemorrhage; Humans; Pyridines; Recurrence; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism	2016
Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future cardiology, 2016, Volume: 12, Issue:4 Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism	2016
[THE IMPORTANCE OF ANTICOAGULANT THERAPY IN PATIENTS WITH ARTIAL FIBRILLATION IN STROKE PREVENTION--SUMMARY OF INTERNATIONAL DATA AND NOVEL THERAPEUTIC MODALITIES]. Ideggyogyaszati szemle, 2016, Mar-30, Volume: 69, Issue:3-4 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Humans; Prevalence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles	2016
Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. Journal of the American Heart Association, 2016, 05-20, Volume: 5, Issue:5 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Intracranial Hemorrhages; Network Meta-Analysis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF. Journal of the American College of Cardiology, 2016, 06-21, Volume: 67, Issue:24 Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Dabigatran; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Kidney Failure, Chronic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
[Anticoagulation for patients with non-valvular atrial fibrillation]. Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74, Issue:4 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thrombolytic Therapy; Warfarin	2016
Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vascular health and risk management, 2016, Volume: 12 Topics: Administration, Oral; Atrial Fibrillation; Blood Coagulation; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Venous Thromboembolism	2016
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Administration, Oral; Anticoagulants; Antidotes; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2016
Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban. The International journal of neuroscience, 2017, Volume: 127, Issue:8 Topics: Atrial Fibrillation; Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Thiazoles	2017
Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis. JACC. Heart failure, 2016, Volume: 4, Issue:11 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Cardiovascular Diseases; Cause of Death; Dabigatran; Embolism; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Intracranial Hemorrhages; Mortality; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2016
Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile. Future cardiology, 2017, Volume: 13, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles	2017
The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert review of clinical pharmacology, 2017, Volume: 10, Issue:1 Topics: Animals; Atrial Fibrillation; Dose-Response Relationship, Drug; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles	2017
Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:1 Topics: Administration, Oral; Aged; Atrial Fibrillation; Factor Xa Inhibitors; Heart Failure; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism	2017
Comparative Efficacy of Clinical Events Prevention of Five Anticoagulants in Patients With Atrial Fibrillation (A Network Meta-Analysis). The American journal of cardiology, 2017, Feb-15, Volume: 119, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Mortality; Myocardial Infarction; Network Meta-Analysis; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
Edoxaban: A direct oral anticoagulant. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2017, 02-01, Volume: 74, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Drug Monitoring; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2017
Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Advances in therapy, 2017, Volume: 34, Issue:3 Topics: Age Factors; Anticoagulants; Atrial Fibrillation; Comparative Effectiveness Research; Humans; Medication Therapy Management; Practice Guidelines as Topic; Pyridines; Thiazoles; Venous Thromboembolism; Warfarin	2017
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions. Seminars in respiratory and critical care medicine, 2017, Volume: 38, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Forecasting; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2017
Anticoagulation Therapy and NOACs in Heart Failure. Handbook of experimental pharmacology, 2017, Volume: 243 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Heart Failure; Hemorrhage; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2017
[Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wiener medizinische Wochenschrift (1946), 2018, Volume: 168, Issue:5-6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism	2018
New anticoagulants for atrial fibrillation. Seminars in thrombosis and hemostasis, 2009, Volume: 35, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; Biotin; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Oligosaccharides; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K	2009
Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation. Current opinion in cardiology, 2010, Volume: 25, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Benzamides; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thromboembolism; Warfarin	2010
[Research and development strategy of antithrombotic agents: pharmacology of the oral factor Xa-inhibitor edoxaban]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2010, Volume: 136, Issue:2 Topics: Administration, Oral; Animals; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Drug Design; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Intracranial Thrombosis; Postoperative Complications; Pyridines; Secondary Prevention; Thiazoles; Thrombosis; Venous Thrombosis	2010
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annual review of medicine, 2011, Volume: 62 Topics: Acute Coronary Syndrome; Amidines; Anticoagulants; Atrial Fibrillation; Azetidines; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Thromboembolism; Treatment Outcome; Vitamin K	2011
[Thromboembolic prophylaxis 2011: is warfarin on the wane?]. Giornale italiano di cardiologia (2006), 2011, Volume: 12, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzamides; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Evidence-Based Medicine; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Thiazoles; Thiophenes; Thromboembolism; Treatment Outcome; Warfarin	2011
[Current status and future of anti-Xa inhibitors]. Rinsho shinkeigaku = Clinical neurology, 2011, Volume: 51, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Azepines; Benzamides; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes	2011
Current and future alternatives to warfarin for the prevention of stroke in atrial fibrillation. Critical pathways in cardiology, 2012, Volume: 11, Issue:2 Topics: Anticoagulants; Antithrombin Proteins; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; Chemoprevention; Dabigatran; Fibrinolytic Agents; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2012
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2012, Volume: 35, Issue:1 Topics: Anticoagulants; Antithrombins; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Hemorrhage; Humans; Morpholines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Risk Assessment; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombolytic Therapy; Ticlopidine; Warfarin	2012
[New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation]. Kardiologia polska, 2012, Volume: 70, Issue:10 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Electric Countershock; Factor Xa Inhibitors; Humans; Kidney Failure, Chronic; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2012
The novel anticoagulants: the surgeons' prospective. Surgery, 2013, Volume: 153, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Blood Loss, Surgical; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surgical Procedures, Operative; Thiazoles; Thiophenes; Venous Thromboembolism; Warfarin	2013

Trials

89 trial(s) available for thiazoles and Atrial Fibrillation

Article	Year
Edoxaban Exposure in Patients With Atrial Fibrillation and Estimated Creatinine Clearance Exceeding 100 mL/min. Clinical pharmacology in drug development, 2022, Volume: 11, Issue:5 Topics: Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2022
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. European heart journal. Cardiovascular pharmacotherapy, 2022, Sep-29, Volume: 8, Issue:7 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Peripheral Arterial Disease; Pyridines; Stroke; Thiazoles; Warfarin	2022
Edoxaban versus Warfarin in high-risk patients with atrial fibrillation: A comprehensive analysis of high-risk subgroups. American heart journal, 2022, Volume: 247 Topics: Aged; Anticoagulants; Atrial Fibrillation; Body Weight; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2022
Efficacy and Safety of Edoxaban 15 mg According to Renal Function in Very Elderly Patients With Atrial Fibrillation: A Subanalysis of the ELDERCARE-AF Trial. Circulation, 2022, Volume: 145, Issue:9 Topics: Aged, 80 and over; Atrial Fibrillation; Female; Humans; Kidney Function Tests; Male; Pyridines; Thiazoles	2022
Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial. JAMA cardiology, 2022, 06-01, Volume: 7, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin	2022
Rationale design and efficacy of a smartphone application for improving self-awareness of adherence to edoxaban treatment: study protocol for a randomised controlled trial (adhere app). BMJ open, 2022, 04-27, Volume: 12, Issue:4 Topics: Atrial Fibrillation; Humans; Mobile Applications; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Smartphone; Stroke; Thiazoles	2022
Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial. JAMA network open, 2022, 08-01, Volume: 5, Issue:8 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Embolism; Factor Xa Inhibitors; Female; Frail Elderly; Frailty; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles	2022
Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub-Analysis of the ELDERCARE-AF Trial. Journal of the American Heart Association, 2022, 09-06, Volume: 11, Issue:17 Topics: Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin	2022
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, Nov-01, Volume: 21, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Therapy, Combination; Echocardiography, Transesophageal; Electric Countershock; Factor Xa Inhibitors; Female; Heart Atria; Heart Diseases; Humans; Male; Prospective Studies; Pyridines; Thiazoles; Thrombosis; Treatment Outcome; Warfarin	2019
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet (London, England), 2019, Oct-12, Volume: 394, Issue:10206 Topics: Acute Coronary Syndrome; Aged; Atrial Fibrillation; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Stents; Stroke; Thiazoles; Vitamin K	2019
Efficacy and Safety of Uninterrupted Periprocedural Edoxaban in Patients Undergoing Catheter Ablation for Atrial Fibrillation　- The Prospective KYU-RABLE Study. Circulation journal : official journal of the Japanese Circulation Society, 2019, 09-25, Volume: 83, Issue:10 Topics: Administration, Oral; Aged; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Prospective Studies; Pyridines; Risk Factors; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome	2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 Trial. Circulation, 2019, 11-26, Volume: 140, Issue:22 Topics: Aged; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Middle Aged; Pyridines; Risk Factors; Thiazoles; Warfarin	2019
Activated clotting time on the day of atrial fibrillation ablation for minimally interrupted and uninterrupted direct oral anticoagulation therapy: Sequential changes, differences among direct oral anticoagulants, and ablation safety outcomes. Journal of cardiovascular electrophysiology, 2019, Volume: 30, Issue:12 Topics: Action Potentials; Aged; Antithrombins; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Dabigatran; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Female; Heart Rate; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Thiazoles; Time Factors; Treatment Outcome; Whole Blood Coagulation Time	2019
Edoxaban versus warfarin in vitamin K antagonist experienced and naïve patients from the edoxaban versus warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomised trial. Clinical research in cardiology : official journal of the German Cardiac Society, 2020, Volume: 109, Issue:8 Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2020
Efficacy and safety of edoxaban in patients with diabetes mellitus in the ENGAGE AF-TIMI 48 trial. International journal of cardiology, 2020, 04-01, Volume: 304 Topics: Anticoagulants; Atrial Fibrillation; Diabetes Mellitus; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome	2020
[ETNA-AF study: Italian baseline data and comparison with the European population in atrial fibrillation patients treated with edoxaban]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:2 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Female; Humans; Italy; Male; Middle Aged; Pyridines; Registries; Thiazoles; Thromboembolism	2020
Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial. Clinical research in cardiology : official journal of the German Cardiac Society, 2020, Volume: 109, Issue:11 Topics: Aged; Atrial Fibrillation; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin	2020
Point-of-care testing of coagulation in patients treated with edoxaban. Journal of thrombosis and thrombolysis, 2020, Volume: 50, Issue:3 Topics: Aged; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Point-of-Care Testing; Prospective Studies; Pyridines; Stroke; Thiazoles	2020
[One-year follow-up of Italian patients with atrial fibrillation treated with edoxaban in ETNA-AF Europe]. Giornale italiano di cardiologia (2006), 2020, Volume: 21, Issue:7 Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Italy; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles; Thromboembolism	2020
Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. European heart journal, 2020, 12-14, Volume: 41, Issue:47 Topics: Acute Coronary Syndrome; Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pyridines; Stroke; Thiazoles; Treatment Outcome	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation. The New England journal of medicine, 2020, 10-29, Volume: 383, Issue:18 Topics: Aged, 80 and over; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Male; Patient Dropouts; Pyridines; Stroke; Thiazoles	2020
Cardiovascular- and Bleeding-Related Hospitalization Rates With Edoxaban Versus Warfarin in Patients With Atrial Fibrillation Based on Results of the ENGAGE AF-TIMI 48 Trial. Circulation. Cardiovascular quality and outcomes, 2020, Volume: 13, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Factor Xa Inhibitors; Female; Hemorrhage; Hospitalization; Humans; Male; Middle Aged; Pyridines; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2020
Periprocedural anticoagulation in the uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation (ELIMINATE-AF) trial. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2021, 01-27, Volume: 23, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Heparin; Humans; Pyridines; Thiazoles; Treatment Outcome; Vitamin K	2021
Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC medicine, 2020, 12-24, Volume: 18, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Follow-Up Studies; Frailty; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Prognosis; Pyridines; Thiazoles; Treatment Outcome; Warfarin	2020
Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation with warfarin or edoxaban: An in-depth analysis from the ENGAGE AF-TIMI 48 randomized trial. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2021, Volume: 86 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Intracranial Hemorrhages; Male; Middle Aged; Pyridines; Thiazoles; Warfarin	2021
Randomized, Double-Blind Comparison of Half-Dose Versus Full-Dose Edoxaban in 14,014 Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2021, 03-09, Volume: 77, Issue:9 Topics: Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Thiazoles	2021
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. The New England journal of medicine, 2021, 12-02, Volume: 385, Issue:23 Topics: 4-Hydroxycoumarins; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Mortality; Phenindione; Postoperative Complications; Pyridines; Thiazoles; Thromboembolism; Transcatheter Aortic Valve Replacement; Vitamin K	2021
First experience with edoxaban and atrial fibrillation ablation - Insights from the ENGAGE AF-TIMI 48 trial. International journal of cardiology, 2017, Oct-01, Volume: 244 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Pyridines; Thiazoles; Thrombolytic Therapy; Warfarin	2017
Probing oral anticoagulation in patients with atrial high rate episodes: Rationale and design of the Non-vitamin K antagonist Oral anticoagulants in patients with Atrial High rate episodes (NOAH-AFNET 6) trial. American heart journal, 2017, Volume: 190 Topics: Administration, Oral; Aged; Aspirin; Atrial Fibrillation; Disease-Free Survival; Double-Blind Method; Europe; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Heart Rate; Humans; Incidence; Male; Prospective Studies; Pyridines; Risk Factors; Stroke; Survival Rate; Thiazoles; Time Factors; Treatment Outcome; Vitamin K	2017
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2017, Aug-11, Volume: 6, Issue:8 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Health Status; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Quality of Life; Risk Factors; Stroke; Surveys and Questionnaires; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2017
The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American heart journal, 2017, Volume: 193 Topics: Aged; Anticoagulants; Atrial Fibrillation; Creatinine; Dose-Response Relationship, Drug; Electric Countershock; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2017
Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study. American heart journal, 2017, Volume: 194 Topics: Administration, Oral; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Incidence; Japan; Male; Pyridines; Stroke; Survival Rate; Thiazoles; Treatment Outcome; Warfarin	2017
Clinical events after interruption of anticoagulation in patients with atrial fibrillation: An analysis from the ENGAGE AF-TIMI 48 trial. International journal of cardiology, 2018, 04-15, Volume: 257 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pyridines; Retrospective Studies; Risk Factors; Stroke; Thiazoles; Thromboembolism; Warfarin; Withholding Treatment	2018
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. American heart journal, 2018, Volume: 196 Topics: Administration, Oral; Atrial Fibrillation; Drug Therapy, Combination; Female; Fibrinolytic Agents; Humans; Internationality; Male; Patient Safety; Percutaneous Coronary Intervention; Postoperative Complications; Pyridines; Risk Assessment; Single-Blind Method; Stents; Survival Rate; Thiazoles; Treatment Outcome	2018
Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). International journal of cardiology, 2018, 07-01, Volume: 262 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Body Mass Index; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Obesity; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K	2018
Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study. Clinical cardiology, 2018, Volume: 41, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Brain Ischemia; Catheter Ablation; Clinical Protocols; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Pyridines; Research Design; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin	2018
Peri-operative Adverse Outcomes in Patients with Atrial Fibrillation Taking Warfarin or Edoxaban: Analysis of the ENGAGE AF-TIMI 48 Trial. Thrombosis and haemostasis, 2018, Volume: 118, Issue:6 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cardiac Surgical Procedures; Double-Blind Method; Female; Hemorrhage; Humans; Male; Perioperative Care; Postoperative Complications; Pyridines; Stroke; Thiazoles; Treatment Outcome; United States; Warfarin	2018
Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2018, 12-01, Volume: 20, Issue:12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Echocardiography, Transesophageal; Electric Countershock; Emergency Service, Hospital; Europe; Factor Xa Inhibitors; Female; Hemorrhage; Hospital Costs; Humans; Male; Middle Aged; Patient Readmission; Patient Satisfaction; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States; Warfarin	2018
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. European heart journal. Acute cardiovascular care, 2019, Volume: 8, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Coronary Angiography; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Pyridines; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin	2019
Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design. Clinical cardiology, 2018, Volume: 41, Issue:9 Topics: Administration, Oral; Aged; Atrial Fibrillation; Dose-Response Relationship, Drug; Europe; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Middle Aged; Prospective Studies; Pyridines; Secondary Prevention; Stroke; Thiazoles	2018
Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone Transcatheter Aortic Valve Implantation in Atrial Fibrillation-Rationale and design of the ENVISAGE-TAVI AF trial. American heart journal, 2018, Volume: 205 Topics: Aortic Valve; Aortic Valve Stenosis; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Standard of Care; Thiazoles; Thromboembolism; Thrombolytic Therapy; Transcatheter Aortic Valve Replacement; Treatment Outcome	2018
Edoxaban Versus Warfarin in Latin American Patients With Atrial Fibrillation: The ENGAGE AF-TIMI 48 Trial. Journal of the American College of Cardiology, 2018, 09-25, Volume: 72, Issue:13 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hospitalization; Humans; Intracranial Hemorrhages; Latin America; Male; Myocardial Infarction; Pyridines; Stroke; Thiazoles; Warfarin	2018
Impact of periprocedural anticoagulation therapy on the incidence of silent stroke after atrial fibrillation ablation in patients receiving direct oral anticoagulants: uninterrupted vs. interrupted by one dose strategy. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, Apr-01, Volume: 21, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Asymptomatic Diseases; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Peptide Fragments; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Prospective Studies; Prothrombin; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles	2019
Edoxaban and implantable cardiac device interventions: insights from the ENGAGE AF-TIMI 48 trial. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2019, Feb-01, Volume: 21, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cardiac Resynchronization Therapy Devices; Defibrillators, Implantable; Device Removal; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pacemaker, Artificial; Prosthesis Implantation; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2019
Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Aged; American Indian or Alaska Native; Anticoagulants; Asian People; Atrial Fibrillation; Black People; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin; White People	2019
Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Body Mass Index; Comorbidity; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Obesity; Overweight; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2019
Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial. American heart journal, 2019, Volume: 209 Topics: Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Electric Countershock; Factor Xa Inhibitors; Female; Follow-Up Studies; Heart Rate; Humans; Male; Middle Aged; Pyridines; Remission, Spontaneous; Retrospective Studies; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2019
Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. Clinical pharmacokinetics, 2019, Volume: 58, Issue:9 Topics: Administration, Oral; Adolescent; Adult; Atrial Fibrillation; Case-Control Studies; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Young Adult	2019
Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. European heart journal, 2019, 09-21, Volume: 40, Issue:36 Topics: Aged; Atrial Fibrillation; Catheter Ablation; Cerebral Hemorrhage; Factor Xa Inhibitors; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Hemorrhage; Pyridines; Stroke; Thiazoles; Vitamin K	2019
Design and rationale of the STroke secondary prevention with catheter ABLation and EDoxaban clinical trial in patients with non-valvular atrial fibrillation: The STABLED study. Journal of cardiology, 2019, Volume: 74, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Embolism; Female; Humans; Japan; Male; Prospective Studies; Pyridines; Recurrence; Secondary Prevention; Stroke; Thiazoles	2019
Edoxaban Versus Warfarin Stratified by Average Blood Pressure in 19 679 Patients With Atrial Fibrillation and a History of Hypertension in the ENGAGE AF-TIMI 48 Trial. Hypertension (Dallas, Tex. : 1979), 2019, Volume: 74, Issue:3 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Comorbidity; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Logistic Models; Male; Patient Safety; Prognosis; Proportional Hazards Models; Pyridines; Risk Assessment; Severity of Illness Index; Stroke; Survival Analysis; Thiazoles; Treatment Outcome; Warfarin	2019
Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine, 2013, Nov-28, Volume: 369, Issue:22 Topics: Adult; Aged; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Double-Blind Method; Embolism; Female; Follow-Up Studies; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin	2013
Left atrial structure and function in atrial fibrillation: ENGAGE AF-TIMI 48. European heart journal, 2014, Jun-07, Volume: 35, Issue:22 Topics: Aged; Anticoagulants; Atrial Fibrillation; Atrial Function, Left; Double-Blind Method; Echocardiography; Female; Heart Atria; Humans; Male; Prospective Studies; Pyridines; Stroke Volume; Thiazoles; Ventricular Function, Left; Ventricular Remodeling	2014
Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke, 2014, Volume: 45, Issue:8 Topics: Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2014
Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial. Journal of the American College of Cardiology, 2014, Aug-12, Volume: 64, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Substitution; Factor Xa; Female; Humans; Male; Middle Aged; Myocardial Infarction; Pyridines; Thiazoles; Treatment Outcome; Warfarin	2014
Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. European journal of clinical pharmacology, 2014, Volume: 70, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Dose-Response Relationship, Drug; Female; Hemorrhage; Humans; Male; Middle Aged; Models, Biological; Pyridines; Quinidine; Renal Insufficiency; Thiazoles; Young Adult	2014
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†. European heart journal, 2015, Jun-14, Volume: 36, Issue:23 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Warfarin	2015
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet (London, England), 2015, Jun-06, Volume: 385, Issue:9984 Topics: Anticoagulants; Atrial Fibrillation; Cytochrome P-450 CYP2C9; Double-Blind Method; Factor Xa Inhibitors; Genetic Variation; Genotype; Hemorrhage; Humans; International Normalized Ratio; Pharmacogenetics; Pyridines; Risk Assessment; Stroke; Thiazoles; Vitamin K Epoxide Reductases; Warfarin	2015
Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet (London, England), 2015, Jun-06, Volume: 385, Issue:9984 Topics: Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome	2015
Short-Term Safety and Plasma Concentrations of Edoxaban in Japanese Patients With Non-Valvular Atrial Fibrillation and Severe Renal Impairment. Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:7 Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Factor Xa Inhibitors; Female; Fibrinolysis; Humans; Japan; Male; Middle Aged; Pyridines; Renal Insufficiency, Chronic; Thiazoles	2015
A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study. American heart journal, 2015, Volume: 169, Issue:5 Topics: Adult; Anticoagulants; Atrial Fibrillation; Cardiovascular Diseases; Electric Countershock; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyridines; Research Design; Stroke; Thiazoles; Thromboembolism; Warfarin	2015
Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. European heart journal, 2015, Sep-01, Volume: 36, Issue:33 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2015
Systemic, noncerebral, arterial embolism in 21,105 patients with atrial fibrillation randomized to edoxaban or warfarin: results from the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction American heart journal, 2015, Volume: 170, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Double-Blind Method; Embolism; Factor Xa; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Middle Aged; Myocardial Infarction; Pyridines; Retrospective Studies; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin	2015
Cost-effectiveness of edoxaban vs warfarin in patients with atrial fibrillation based on results of the ENGAGE AF-TIMI 48 trial. American heart journal, 2015, Volume: 170, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Monitoring; Embolism; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Selection; Pyridines; Risk Assessment; Stroke; Survival Analysis; Thiazoles; Treatment Outcome; Warfarin	2015
Edoxaban vs warfarin in patients with nonvalvular atrial fibrillation in the US Food and Drug Administration approval population: An analysis from the Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardi American heart journal, 2016, Volume: 172 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dose-Response Relationship, Drug; Double-Blind Method; Drug Approval; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Pyridines; Stroke; Thiazoles; Thrombolytic Therapy; United States; United States Food and Drug Administration; Warfarin	2016
Edoxaban vs. Warfarin in East Asian Patients With Atrial Fibrillation　- An ENGAGE AF-TIMI 48 Subanalysis. Circulation journal : official journal of the Japanese Circulation Society, 2016, Volume: 80, Issue:4 Topics: Aged; Aged, 80 and over; Asia, Eastern; Atrial Fibrillation; Double-Blind Method; Embolism; Hemorrhage; Humans; Pyridines; Stroke; Thiazoles; Warfarin	2016
Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. Journal of the American Heart Association, 2016, Feb-23, Volume: 5, Issue:2 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2016
Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial. Clinical pharmacokinetics, 2016, Volume: 55, Issue:9 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Biological Availability; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Healthy Volunteers; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Models, Theoretical; Pyridines; Thiazoles	2016
Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. The American journal of medicine, 2016, Volume: 129, Issue:8 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Treatment Outcome; United States; Warfarin	2016
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48. Clinical cardiology, 2016, Volume: 39, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Atrial Flutter; Combined Modality Therapy; Double-Blind Method; Electric Countershock; Factor Xa Inhibitors; Female; Hemorrhage; Humans; International Normalized Ratio; Male; Pyridines; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2016
Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2016, 05-20, Volume: 5, Issue:5 Topics: Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2016
Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from ENGAGE AF-TIMI 48. European journal of heart failure, 2016, Volume: 18, Issue:9 Topics: Aged; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Heart Failure; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyridines; Stroke; Thiazoles; Treatment Outcome; Warfarin	2016
Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation, 2016, Jul-05, Volume: 134, Issue:1 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Creatinine; Double-Blind Method; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Kidney; Kidney Function Tests; Male; Metabolic Clearance Rate; Middle Aged; Pyridines; Risk; Thiazoles; Thrombophilia; Warfarin	2016
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke, 2016, Volume: 47, Issue:8 Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyridines; Recurrence; Secondary Prevention; Stroke; Thiazoles; Treatment Outcome; Warfarin	2016
Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis? Circulation journal : official journal of the Japanese Circulation Society, 2016, Aug-25, Volume: 80, Issue:9 Topics: Asian People; Atrial Fibrillation; Female; Humans; Japan; Male; Pyridines; Thiazoles	2016
Has the Safety of Edoxaban 60 mg Among East Asian Atrial Fibrillation Patients Been Truly Proven by the ENGAGE AF-TIMI 48 Subanalysis?　- Reply. Circulation journal : official journal of the Japanese Circulation Society, 2016, Aug-25, Volume: 80, Issue:9 Topics: Asian People; Atrial Fibrillation; Female; Humans; Japan; Male; Pyridines; Thiazoles	2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. Lancet (London, England), 2016, Oct-22, Volume: 388, Issue:10055 Topics: Aged; Anticoagulants; Atrial Fibrillation; Electric Countershock; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles; Thromboembolism; Warfarin	2016
Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling: ENGAGE AF-TIMI 48 Analysis. Journal of the American College of Cardiology, 2016, 09-13, Volume: 68, Issue:11 Topics: Accidental Falls; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Risk Factors; Single-Blind Method; Stroke; Thiazoles; Warfarin	2016
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation, 2016, 10-11, Volume: 134, Issue:15 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Drug Labeling; Female; Humans; Kidney Function Tests; Male; Prospective Studies; Pyridines; Registries; Thiazoles; United States; United States Food and Drug Administration	2016
A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. European heart journal, 2017, Mar-21, Volume: 38, Issue:12 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Risk Assessment; Risk Factors; Stroke; Thiazoles; Treatment Outcome; Warfarin	2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Circulation. Arrhythmia and electrophysiology, 2017, Volume: 10, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2017
Edoxaban for the Prevention of Thromboembolism in Patients With Atrial Fibrillation and Bioprosthetic Valves. Circulation, 2017, 03-28, Volume: 135, Issue:13 Topics: Anticoagulants; Atrial Fibrillation; Bioprosthesis; Blood Coagulation; Factor Xa Inhibitors; Heart Valve Prosthesis; Heart Valve Prosthesis Implantation; Hemorrhage; Humans; Pyridines; Risk Factors; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2017
Valvular Heart Disease Patients on Edoxaban or Warfarin in the ENGAGE AF-TIMI 48 Trial. Journal of the American College of Cardiology, 2017, Mar-21, Volume: 69, Issue:11 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Double-Blind Method; Embolism; Female; Heart Valve Diseases; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin	2017
Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and haemostasis, 2010, Volume: 104, Issue:3 Topics: Administration, Oral; Aged; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Atrial Fibrillation; Bilirubin; Biomarkers; Blood Coagulation; Double-Blind Method; Europe, Eastern; Factor Xa; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Time Factors; Treatment Outcome; United States; Warfarin	2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infar American heart journal, 2010, Volume: 160, Issue:4 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Infarction; Pyridines; Retrospective Studies; Stroke; Thiazoles; Thrombolytic Therapy; Treatment Outcome; Warfarin	2010
Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thrombosis and haemostasis, 2011, Volume: 105, Issue:3 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Double-Blind Method; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Middle Aged; Pyridines; Thiazoles; Warfarin	2011
Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thrombosis and haemostasis, 2012, Volume: 107, Issue:5 Topics: Administration, Oral; Anticoagulants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Atrial Fibrillation; Blood Coagulation; Clinical Trials, Phase III as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Interactions; Factor Xa; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Kidney Diseases; Logistic Models; Male; Models, Biological; Models, Statistical; Pyridines; Research Design; Risk Assessment; Risk Factors; Stroke; Thiazoles; Treatment Outcome	2012
Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:8 Topics: Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Female; Hemorrhage; Humans; Incidence; International Normalized Ratio; Japan; Male; Middle Aged; Pyridines; Thiazoles; Warfarin	2012

Other Studies

188 other study(ies) available for thiazoles and Atrial Fibrillation

Article	Year
Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data. Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:9 Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Ischemic Stroke; Japan; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles	2021
Difference in left atrial D-dimer level in patients with atrial fibrillation treated with direct oral anticoagulant. BMC cardiovascular disorders, 2021, 10-09, Volume: 21, Issue:1 Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Biomarkers; Dabigatran; Factor Xa Inhibitors; Female; Fibrin Fibrinogen Degradation Products; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Thiazoles; Treatment Outcome	2021
Comparison of clinical outcomes of edoxaban versus apixaban, dabigatran, rivaroxaban, and vitamin K antagonists in patients with atrial fibrillation in Germany: A real-world cohort study. International journal of cardiology, 2022, Jan-01, Volume: 346 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Cohort Studies; Dabigatran; Humans; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K	2022
Thrombotic events and rebleeding after hemorrhage in patients taking direct oral anticoagulants for non-valvular atrial fibrillation. PloS one, 2021, Volume: 16, Issue:11 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thrombosis	2021
Hip fractures risks in edoxaban versus warfarin users: A propensity score-matched population-based cohort study with competing risk analyses. Bone, 2022, Volume: 156 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Female; Hip Fractures; Humans; Male; Middle Aged; Propensity Score; Pyridines; Retrospective Studies; Risk Assessment; Stroke; Thiazoles; Warfarin	2022
Antiphospholipid Syndrome Diagnosed as a Result of the Occurrence of an Ischemic Stroke After a Successful Catheter Ablation of Atrial Fibrillation and Continuous Direct Oral Anticoagulants. International heart journal, 2022, Volume: 63, Issue:1 Topics: Aged; Antiphospholipid Syndrome; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Humans; Ischemic Stroke; Pyridines; Thiazoles	2022
In AF after TAVR, edoxaban was noninferior to VKAs for a composite of adverse events but increased major bleeding. Annals of internal medicine, 2022, Volume: 175, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Hemorrhage; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement	2022
Azoramide ameliorated tachypacing-induced injury of atrial myocytes differentiated from human induced pluripotent stem cell by regulating endoplasmic reticulum stress. Stem cell research, 2022, Volume: 60 Topics: Adenosine Triphosphate; Amides; Atrial Fibrillation; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Endoplasmic Reticulum Stress; Humans; Induced Pluripotent Stem Cells; Myocytes, Cardiac; Thiazoles	2022
D-dimer levels in patients with nonvalvular atrial fibrillation and acute heart failure treated with edoxaban. Journal of cardiology, 2022, Volume: 79, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Fibrin Fibrinogen Degradation Products; Heart Failure; Humans; Ischemic Stroke; Pyridines; Stroke; Thiazoles	2022
Edoxaban-based long-term antithrombotic therapy in patients with atrial fibrillation and stable coronary disease: Rationale and design of the randomized EPIC-CAD trial. American heart journal, 2022, Volume: 247 Topics: Anticoagulants; Atrial Fibrillation; Coronary Artery Disease; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Pyridines; Stroke; Thiazoles; Treatment Outcome	2022
Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. The New England journal of medicine, 2022, 02-24, Volume: 386, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement; Vitamin K	2022
Edoxaban or Vitamin K Antagonist for Atrial Fibrillation after TAVR. Reply. The New England journal of medicine, 2022, 02-24, Volume: 386, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Transcatheter Aortic Valve Replacement; Vitamin K	2022
Factor Xa inhibitor, edoxaban ameliorates renal injury after subtotal nephrectomy by reducing epithelial-mesenchymal transition and inflammatory response. Physiological reports, 2022, Volume: 10, Issue:5 Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Epithelial-Mesenchymal Transition; Factor Xa Inhibitors; Fibrosis; Inflammation Mediators; Kidney; Mice; Nephrectomy; Pyridines; Renal Insufficiency, Chronic; Thiazoles	2022
Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2022, 03-01, Volume: 50, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Stroke; Thiazoles; Treatment Outcome; Turkey	2022
Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022, 10-13, Volume: 24, Issue:9 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Europe; Female; Frailty; Humans; Prospective Studies; Pyridines; Stroke; Thiazoles	2022
Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY. Thrombosis research, 2022, Volume: 215 Topics: Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; Ischemic Attack, Transient; Prospective Studies; Pyridines; Registries; Stroke; Thiazoles; Treatment Outcome	2022
Swapping patients to edoxaban but at what cost? Drug and therapeutics bulletin, 2023, Volume: 61, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles	2023
Effect of concomitant antiplatelet therapy in patients with nonvalvular atrial fibrillation initiating non-vitamin K antagonists. European journal of clinical investigation, 2019, Volume: 49, Issue:10 Topics: Aged; Aged, 80 and over; Antithrombins; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles	2019
Dual antithrombotic therapy for atrial fibrillation and PCI. Lancet (London, England), 2019, 10-12, Volume: 394, Issue:10206 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2019
Edoxaban noninferior to VKA in AF after PCI. Nature reviews. Cardiology, 2019, Volume: 16, Issue:11 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2019
Association between plasma concentration of edoxaban determined by direct and indirect methods in Japanese patients with non-valvular atrial fibrillation (CVI ARO 7). Heart and vessels, 2020, Volume: 35, Issue:3 Topics: Aged; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Chromatography, Liquid; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Predictive Value of Tests; Pyridines; Registries; Reproducibility of Results; Tandem Mass Spectrometry; Thiazoles; Treatment Outcome	2020
The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design. Clinical cardiology, 2019, Volume: 42, Issue:12 Topics: Atrial Fibrillation; Databases, Factual; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Venous Thromboembolism	2019
NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters? Thrombosis and haemostasis, 2020, Volume: 120, Issue:2 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Cross-Sectional Studies; Dabigatran; Drug Administration Schedule; Female; Humans; Male; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Surveys and Questionnaires; Thiazoles	2020
Oral Anticoagulation in Patients in the Emergency Department: High Rates of Off-Label Doses, No Difference in Bleeding Rates. The American journal of medicine, 2020, Volume: 133, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Emergency Service, Hospital; Female; Hemorrhage; Humans; Male; Off-Label Use; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Vitamin K	2020
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. European heart journal. Cardiovascular pharmacotherapy, 2020, 07-01, Volume: 6, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Comorbidity; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin	2020
Anticoagulants in Atrial Fibrillation and Liver Disease. Journal of the American College of Cardiology, 2019, 11-12, Volume: 74, Issue:19 Topics: Anticoagulants; Atrial Fibrillation; Humans; Liver Diseases; Pyridines; Thiazoles; Warfarin	2019
Effectiveness and safety of edoxaban in patients with atrial fibrillation: data from the Danish Nationwide Cohort. European heart journal. Cardiovascular pharmacotherapy, 2021, 01-16, Volume: 7, Issue:1 Topics: Aged; Atrial Fibrillation; Cohort Studies; Denmark; Female; Humans; Male; Pyridines; Thiazoles	2021
A mixed methodology, non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke associated with non-valvular atrial fibrillation: study protocol. BMC neurology, 2019, Nov-29, Volume: 19, Issue:1 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Humans; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; United Kingdom	2019
Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles. Drug metabolism and pharmacokinetics, 2020, Volume: 35, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation Tests; Chromatography, Liquid; Factor Xa; Factor Xa Inhibitors; Female; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Tandem Mass Spectrometry; Thiazoles; Venous Thromboembolism	2020
Comparing TEE- vs Non-TEE-guided cardioversion of atrial fibrillation: The ENSURE-AF trial. European journal of clinical investigation, 2020, Volume: 50, Issue:5 Topics: Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clinical Decision-Making; Duration of Therapy; Echocardiography, Transesophageal; Electric Countershock; Enoxaparin; Female; Heart Diseases; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Thrombosis; Warfarin	2020
Antithrombotic treatment strategies after PCI. Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2020
Antithrombotic treatment strategies after PCI. Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2020
Antithrombotic treatment strategies after PCI. Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2020
Antithrombotic treatment strategies after PCI. Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2020
Antithrombotic treatment strategies after PCI. Lancet (London, England), 2020, 03-14, Volume: 395, Issue:10227 Topics: Anticoagulants; Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles; Vitamin K	2020
Edoxaban in elderly patient with morbid obesity and atrial fibrillation: the role of plasma levels evaluation for selecting the appropriate dose. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, 2020, Mar-20, Volume: 90, Issue:1 Topics: Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Drug Therapy, Combination; Humans; Male; Obesity, Morbid; Pyridines; Thiazoles	2020
Edoxaban affects TRAP-dependent platelet aggregation. Journal of thrombosis and thrombolysis, 2020, Volume: 49, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Platelet Aggregation; Prospective Studies; Pyridines; Stroke; Thiazoles	2020
Exploratory Analysis of Circulating miRNA Signatures in Atrial Fibrillation Patients Determining Potential Biomarkers to Support Decision-Making in Anticoagulation and Catheter Ablation. International journal of molecular sciences, 2020, Apr-01, Volume: 21, Issue:7 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Biomarkers; Catheter Ablation; Circulating MicroRNA; Decision Making; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Regulatory Networks; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles	2020
Trends in anticoagulant prescribing: a review of local policies in English primary care. BMC health services research, 2020, Apr-03, Volume: 20, Issue:1 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Drug Utilization; England; Female; Humans; Male; Practice Patterns, Physicians'; Primary Health Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; State Medicine; Stroke; Thiazoles; Warfarin	2020
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, 2020, Volume: 48, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cardiologists; Clinical Trials, Phase III as Topic; Consensus; Dabigatran; Disease Management; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin	2020
Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment. Clinical drug investigation, 2020, Volume: 40, Issue:6 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Thiazoles	2020
Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY. Thrombosis research, 2020, Volume: 190 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Prospective Studies; Pyridines; Registries; Stroke; Thiazoles; Treatment Outcome	2020
Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data. Open heart, 2020, Volume: 7, Issue:1 Topics: Administration, Oral; Administrative Claims, Healthcare; Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Electronic Health Records; Female; Hemorrhage; Humans; Japan; Male; Middle Aged; Patient Safety; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Risk Assessment; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome; Vitamin K; Warfarin	2020
Successful Treatment with Edoxaban for Disseminated Intravascular Coagulation in a Case of Aortic Dissection Complicated with Immune Thrombocytopenic Purpura. Internal medicine (Tokyo, Japan), 2020, Aug-15, Volume: 59, Issue:16 Topics: Aged; Anticoagulants; Aortic Dissection; Atrial Fibrillation; Disseminated Intravascular Coagulation; Female; Humans; Platelet Count; Purpura, Thrombocytopenic, Idiopathic; Pyridines; Thiazoles	2020
Routine clinical practice in the periprocedural management of edoxaban therapy is associated with low risk of bleeding and thromboembolic complications: The prospective, observational, and multinational EMIT-AF/VTE study. Clinical cardiology, 2020, Volume: 43, Issue:7 Topics: Adult; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Period; Prospective Studies; Pyridines; Thiazoles; Thromboembolism; Treatment Outcome	2020
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. European heart journal. Cardiovascular pharmacotherapy, 2021, 04-09, Volume: 7, Issue:FI1 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Pyridines; Stroke; Thiazoles	2021
Low-dose edoxaban in elderly patients with AF. Nature reviews. Cardiology, 2020, Volume: 17, Issue:11 Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Thiazoles	2020
A Survey of Direct Oral Anticoagulant Cessation in General Surgery and Outcomes in Patients with Nonvalvular Atrial Fibrillation. International heart journal, 2020, Sep-29, Volume: 61, Issue:5 Topics: Aged; Aged, 80 and over; Antithrombins; Atrial Fibrillation; Blood Loss, Surgical; Carotid Artery Diseases; Cerebral Infarction; Dabigatran; Digestive System Surgical Procedures; Elective Surgical Procedures; Embolism; Endoscopy; Factor Xa Inhibitors; Female; Humans; Male; Myocardial Infarction; Orthopedic Procedures; Perioperative Care; Postoperative Complications; Postoperative Hemorrhage; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Thiazoles; Thromboembolism; Urologic Surgical Procedures; Vascular Surgical Procedures	2020
Non-vitamin K antagonist oral anticoagulants in very elderly east Asians with atrial fibrillation: A nationwide population-based study. American heart journal, 2020, Volume: 229 Topics: Aged, 80 and over; Atrial Fibrillation; Brain Ischemia; Databases, Factual; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Stroke; Thiazoles; Vitamin K; Warfarin	2020
Direct Current Cardioversion in Atrial Fibrillation Patients on Edoxaban Therapy Versus Vitamin K Antagonists: a Real-world Propensity Score-Matched Study. Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:5 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Electric Countershock; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Medication Adherence; Middle Aged; Propensity Score; Pyridines; Stroke; Thiazoles; Vitamin K	2021
Comparisons of Edoxaban Versus Warfarin on Levels of Plasma Prothrombin Fragment in Patients With Nonvalvular Atrial Fibrillation. The American journal of cardiology, 2020, 12-01, Volume: 136 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Peptide Fragments; Prospective Studies; Prothrombin; Pyridines; Stroke; Thiazoles; Warfarin	2020
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET. Blood transfusion = Trasfusione del sangue, 2020, Volume: 18, Issue:6 Topics: Administration, Oral; Antidotes; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Drug Interactions; Drug Monitoring; Glomerular Filtration Rate; Hemorrhage; Humans; Kidney; Metabolic Clearance Rate; Observational Studies as Topic; Polypharmacy; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Rivaroxaban; Stroke; Thiazoles	2020
Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. European heart journal, 2020, 10-21, Volume: 41, Issue:40 Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles	2020
Antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: balance best with double antithrombotic therapy. European heart journal, 2020, 12-14, Volume: 41, Issue:47 Topics: Atrial Fibrillation; Fibrinolytic Agents; Humans; Percutaneous Coronary Intervention; Pyridines; Thiazoles	2020
Association of risk factors and bleeding complications in Asian patients taking edoxaban. British journal of clinical pharmacology, 2021, Volume: 87, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Risk Factors; Thiazoles; Treatment Outcome	2021
Atrial fibrillation management: Time for new goals. Revista portuguesa de cardiologia, 2020, Volume: 39, Issue:11 Topics: Atrial Fibrillation; Goals; Humans; Pyridines; Thiazoles; Time	2020
Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data. Revista portuguesa de cardiologia, 2020, Volume: 39, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Male; Pyridines; Stroke; Thiazoles	2020
A Comparative Prospective Observational Study on the Use of Direct Oral Anticoagulants after Cardiac Surgery for the Management of Atrial Fibrillation. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2021, Jun-20, Volume: 27, Issue:3 Topics: Aged; Atrial Fibrillation; Cardiac Surgical Procedures; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Time Factors; Treatment Outcome	2021
Elderly patients with atrial fibrillation in routine clinical practice-peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, ob BMC cardiovascular disorders, 2020, 12-01, Volume: 20, Issue:1 Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Asia; Atrial Fibrillation; Cerebrovascular Disorders; Drug Administration Schedule; Europe; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Perioperative Care; Postoperative Hemorrhage; Prospective Studies; Pyridines; Registries; Risk Assessment; Risk Factors; Thiazoles; Thromboembolism; Treatment Outcome	2020
Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: A population-based cohort study. American heart journal, 2021, Volume: 233 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Databases, Factual; Deductibles and Coinsurance; Drug Costs; Factor Xa Inhibitors; Female; Humans; Male; Medicare Part C; Medication Adherence; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sample Size; Stroke; Thiazoles; United States; Warfarin	2021
In older patients with AF, low-dose edoxaban reduced stroke or systemic embolism without increasing major bleeding. Annals of internal medicine, 2021, Volume: 174, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Embolism; Humans; Pyridines; Stroke; Thiazoles; Treatment Outcome	2021
Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. Acta cardiologica, 2021, Volume: 76, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Belgium; Europe; Factor Xa Inhibitors; Humans; Netherlands; Prospective Studies; Pyridines; Thiazoles; Treatment Outcome	2021
[Periprocedural edoxaban interruption is associated with low bleeding and thromboembolic risk: the Italian data of the EMIT-AF/VTE study]. Giornale italiano di cardiologia (2006), 2021, Volume: 22, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Hemorrhage; Humans; Italy; Pyridines; Stroke; Thiazoles; Venous Thromboembolism	2021
Low-Dose Edoxaban Effective for Stroke Prevention in Older Patients with Atrial Fibrillation. American family physician, 2021, 03-01, Volume: 103, Issue:5 Topics: Aged; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles	2021
Praxis, 2021, Volume: 110, Issue:3 Topics: Atrial Fibrillation; Humans; Pyridines; Thiazoles	2021
Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. Journal of the Chinese Medical Association : JCMA, 2021, 05-01, Volume: 84, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Databases, Factual; Factor Xa Inhibitors; Female; Humans; Male; Middle Aged; Pyridines; Republic of Korea; Stroke; Taiwan; Thiazoles	2021
Plasma Concentration and Pharmacodynamics of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Acute Heart Failure. Clinical pharmacokinetics, 2021, Volume: 60, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Heart Failure; Humans; Pyridines; Thiazoles	2021
Adverse Events Associated With the Addition of Aspirin to Direct Oral Anticoagulant Therapy Without a Clear Indication. JAMA internal medicine, 2021, 06-01, Volume: 181, Issue:6 Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles; Venous Thromboembolism	2021
How lower doses of direct oral anticoagulants are interpreted in clinical practice: a national survey of the Italian Atherosclerosis, Thrombosis and Vascular Biology (ATVB) Study Group. Journal of cardiovascular medicine (Hagerstown, Md.), 2021, Dec-01, Volume: 22, Issue:11 Topics: Administration, Oral; Anticoagulants; Atherosclerosis; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Italy; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency; Rivaroxaban; Surveys and Questionnaires; Thiazoles; Thrombosis; Treatment Outcome	2021
Use of oral anticoagulants in patients with valvular atrial fibrillation: findings from the NCDR PINNACLE Registry. American heart journal, 2021, Volume: 240 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Male; Practice Patterns, Physicians'; Pyrazoles; Pyridines; Pyridones; Registries; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Warfarin	2021
Unsolved issues of The Efficacy and Safety of Edoxaban. Anatolian journal of cardiology, 2021, Volume: 25, Issue:6 Topics: Atrial Fibrillation; Humans; Pyridines; Thiazoles; Warfarin	2021
Bleeding complications in patients with gastrointestinal cancer and atrial fibrillation treated with oral anticoagulants. Cancer medicine, 2021, Volume: 10, Issue:13 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cohort Studies; Confidence Intervals; Dabigatran; Denmark; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2021
Comparative effectiveness and safety of edoxaban versus warfarin in patients with atrial fibrillation: A nationwide cohort study. International journal of stroke : official journal of the International Stroke Society, 2022, Volume: 17, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2022
Catheter Ablation Energy Sources and Myocardial Injury and Coagulation Biomarkers During Uninterrupted Periprocedural Edoxaban Use　- A Subanalysis of KYU-RABLE. Circulation journal : official journal of the Japanese Circulation Society, 2022, 01-25, Volume: 86, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Biomarkers; Catheter Ablation; Heart Injuries; Hemorrhage; Humans; Pyridines; Thiazoles; Treatment Outcome	2022
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. Journal of the American College of Cardiology, 2021, 08-10, Volume: 78, Issue:6 Topics: Atrial Fibrillation; Biomarkers; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Proteomics; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Thiazoles; Thromboembolism	2021
Comparison of the Incidences of Complications After Second-Generation Cryoballoon Ablation of Atrial Fibrillation Using Vitamin K Antagonists Versus Novel Oral Anticoagulants. The American journal of cardiology, 2017, Jul-15, Volume: 120, Issue:2 Topics: Ablation Techniques; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Belgium; Cryosurgery; Dabigatran; Dose-Response Relationship, Drug; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Intraoperative Period; Italy; Male; Middle Aged; Postoperative Complications; Prognosis; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Survival Rate; Thiazoles; Time Factors; Vitamin K	2017
Cost-Effectiveness of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation Based on Results of the ENGAGE AF - TIMI 48 Trial: Taiwanese Perspective. Value in health regional issues, 2017, Volume: 12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Quality-Adjusted Life Years; Taiwan; Thiazoles; Warfarin	2017
Choice of oral anticoagulants in older patients with non-valvular atrial fibrillation. British journal of hospital medicine (London, England : 2005), 2017, Jul-02, Volume: 78, Issue:7 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Craniocerebral Trauma; Dabigatran; Gastrointestinal Hemorrhage; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Stroke; Thiazoles; Warfarin	2017
Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study. PloS one, 2017, Volume: 12, Issue:7 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
A comparison between vitamin K antagonists and new oral anticoagulants. British journal of clinical pharmacology, 2017, Volume: 83, Issue:11 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Intracranial Hemorrhages; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Vitamin K; Warfarin	2017
Edoxaban Use in Nonvalvular Atrial Fibrillation With Valvular Heart Disease-Insights from ENGAGE AF-TIMI 48. Clinical cardiology, 2017, Volume: 40, Issue:8 Topics: Atrial Fibrillation; Heart Valve Diseases; Humans; Pyridines; Thiazoles	2017
Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, Volume: 70, Issue:6 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Hemorrhage; Humans; Kidney Failure, Chronic; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Renal Dialysis; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Humans; Japan; Magnetic Resonance Imaging; Male; Pyrazoles; Pyridines; Pyridones; Recurrence; Retrospective Studies; Risk Factors; Rivaroxaban; Secondary Prevention; Stroke; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2018
Use of direct oral anticoagulants in the first year after market entry of edoxaban: A Danish nationwide drug utilization study. Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:2 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Denmark; Drug Utilization; Female; Humans; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Stroke; Thiazoles	2018
Safety of Uninterrupted Periprocedural Edoxaban Versus Phenprocoumon for Patients Who Underwent Left Atrial Catheter Ablation Procedures. The American journal of cardiology, 2018, 02-15, Volume: 121, Issue:4 Topics: Aged; Anticoagulants; Atrial Fibrillation; Electrocardiography; Factor Xa Inhibitors; Female; Humans; International Normalized Ratio; Male; Middle Aged; Phenprocoumon; Pulmonary Veins; Pyridines; Radiofrequency Ablation; Thiazoles; Treatment Outcome	2018
Differences in activated clotting time and initial heparin dosage during atrial fibrillation ablation for patients with edoxaban compared with warfarin. Journal of cardiovascular electrophysiology, 2018, Volume: 29, Issue:6 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Catheter Ablation; Factor Xa Inhibitors; Female; Heparin; Humans; Male; Middle Aged; Perioperative Period; Predictive Value of Tests; Pyridines; Thiazoles; Time Factors; Treatment Outcome; Warfarin; Whole Blood Coagulation Time	2018
[The efficacy and safety of edoxaban in non-valvular atrial fibrillation]. Orvosi hetilap, 2018, Volume: 159, Issue:12 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Thrombolytic Therapy; Warfarin	2018
Tromboc@t Working Group recommendations for management in patients receiving direct oral anticoagulants. Medicina clinica, 2018, 09-14, Volume: 151, Issue:5 Topics: Administration, Oral; Age Factors; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Edoxaban (Savaysa) for the Prevention of Thromboembolic Events. American family physician, 2018, 04-15, Volume: 97, Issue:8 Topics: Atrial Fibrillation; Cost-Benefit Analysis; Factor Xa Inhibitors; Humans; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Treatment Outcome; Venous Thrombosis	2018
Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2018, Volume: 18, Issue:4 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk Adjustment; Rivaroxaban; Stroke; Therapeutic Equivalency; Thiazoles; Warfarin	2018
Gastrointestinal Bleeding With Edoxaban Versus Warfarin: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction). Circulation. Cardiovascular quality and outcomes, 2018, Volume: 11, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Dose-Response Relationship, Drug; Drug Monitoring; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pyridines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; Warfarin	2018
Predictors of self-reported adherence to direct oral anticoagulation in a population of elderly men and women with non-valvular atrial fibrillation. Journal of thrombosis and thrombolysis, 2018, Volume: 46, Issue:2 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Caregivers; Dabigatran; Female; Humans; Male; Medication Adherence; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Self Report; Thiazoles	2018
Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation: To Stop, Bridge or Continue? Thrombosis and haemostasis, 2018, Volume: 118, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Humans; Pyridines; Thiazoles; Warfarin	2018
Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node. European journal of pharmacology, 2018, Aug-15, Volume: 833 Topics: Action Potentials; Animals; Atrial Fibrillation; Factor Xa Inhibitors; Guanidines; Male; Microelectrodes; Models, Animal; Myocytes, Cardiac; Oligopeptides; Patch-Clamp Techniques; Pulmonary Veins; Pyridines; Rabbits; Ranolazine; Receptor, PAR-1; Rivaroxaban; Sinoatrial Node; Sodium-Calcium Exchanger; Stroke; Thiazoles	2018
Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety. Journal of the American College of Cardiology, 2018, 08-21, Volume: 72, Issue:8 Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Middle Aged; Mortality; National Health Programs; Pyridines; Republic of Korea; Stroke; Thiazoles; Treatment Outcome	2018
Edoxaban's Journey: From East Asia to the Globe, Back to East Asia. Journal of the American College of Cardiology, 2018, 08-21, Volume: 72, Issue:8 Topics: Asia; Atrial Fibrillation; Humans; Pyridines; Thiazoles	2018
The Comparison of Inappropriate-Low-Doses Use among 4 Direct Oral Anticoagulants in Patients with Atrial Fibrillation: From the Database of a Single-Center Registry. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2018, Volume: 27, Issue:11 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Chi-Square Distribution; Dabigatran; Databases, Factual; Drug Dosage Calculations; Female; Hemorrhage; Humans; Inappropriate Prescribing; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Odds Ratio; Prevalence; Pyrazoles; Pyridines; Pyridones; Registries; Retrospective Studies; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome	2018
Pharmacokinetics of anticoagulants apixaban, dabigatran, edoxaban and rivaroxaban in elderly Japanese patients with atrial fibrillation treated in one general hospital. Xenobiotica; the fate of foreign compounds in biological systems, 2019, Volume: 49, Issue:9 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Female; Humans; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles	2019
Edoxaban in Latin America. Journal of the American College of Cardiology, 2018, 09-25, Volume: 72, Issue:13 Topics: Atrial Fibrillation; Humans; Latin America; Pyridines; Thiazoles; Warfarin	2018
[Edoxaban in patients with atrial fibrillation and cancer]. Giornale italiano di cardiologia (2006), 2018, Volume: 19, Issue:9 Suppl 1 Topics: Anticoagulants; Atrial Fibrillation; Cancer Survivors; Cardiovascular Diseases; Embolism; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Neoplasms; Pyridines; Stroke; Thiazoles; Warfarin	2018
Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke, 2018, Volume: 49, Issue:9 Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Impact of Renal Function on Outcomes With Edoxaban in Real-World Patients With Atrial Fibrillation. Stroke, 2018, Volume: 49, Issue:10 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Embolism; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Warfarin	2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 Trial. Journal of the American Heart Association, 2018, 08-21, Volume: 7, Issue:16 Topics: Aged; Anticoagulants; Atrial Fibrillation; Comorbidity; Embolism; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Proportional Hazards Models; Prostatic Neoplasms; Pyridines; Stroke; Thiazoles; Warfarin	2018
Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation. Journal of the American Heart Association, 2018, 09-04, Volume: 7, Issue:17 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cerebral Angiography; Dabigatran; Diffusion Magnetic Resonance Imaging; Female; Humans; Infarction, Middle Cerebral Artery; International Normalized Ratio; Logistic Models; Magnetic Resonance Angiography; Male; Multivariate Analysis; Prothrombin Time; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin	2018
Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study. Journal of the American Heart Association, 2018, 08-07, Volume: 7, Issue:15 Topics: Aged; Aged, 80 and over; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Hemorrhage; Hepatic Insufficiency; Humans; Male; Proportional Hazards Models; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Thromboembolism; Warfarin	2018
Gastrointestinal bleeding in a patient on multiple medications including edoxaban. British journal of hospital medicine (London, England : 2005), 2018, Nov-02, Volume: 79, Issue:11 Topics: Aged; Arterial Occlusive Diseases; Arthritis, Rheumatoid; Atrial Fibrillation; Drug Interactions; Factor Xa Inhibitors; Gastrointestinal Hemorrhage; Humans; Hypertension; Male; Polypharmacy; Pulmonary Disease, Chronic Obstructive; Pyridines; Thiazoles	2018
Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence. Thrombosis research, 2018, Volume: 172 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Dabigatran; Female; Hemorrhage; Humans; Male; Prognosis; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Secondary Prevention; Thiazoles	2018
Lakartidningen, 2018, 12-04, Volume: 115 Topics: Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Humans; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. Journal of cardiovascular medicine (Hagerstown, Md.), 2019, Volume: 20, Issue:2 Topics: Administration, Oral; Atrial Fibrillation; Europe; Factor Xa Inhibitors; Hemorrhage; Humans; Prospective Studies; Pyridines; Registries; Research Design; Stroke; Thiazoles; Time Factors; Treatment Outcome	2019
Higher Incidence of Ischemic Stroke in Patients Taking Novel Oral Anticoagulants. Stroke, 2018, Volume: 49, Issue:12 Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Dabigatran; Female; Humans; Incidence; Intracranial Hemorrhages; Male; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Anticoagulation Therapy for Atrial Fibrillation in Patients With Alzheimer's Disease. Stroke, 2018, Volume: 49, Issue:12 Topics: Aged; Alzheimer Disease; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Disease Progression; Health Care Costs; Humans; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin	2018
Stroke prevention in AF: Of Asians and non-Asians. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Asian People; Atrial Fibrillation; Humans; Pyridines; Stroke; Thiazoles	2019
Facing real-life with direct oral anticoagulants in patients with nonvalvular atrial fibrillation: outcomes from the first observational and prospective study in a Spanish population. Journal of comparative effectiveness research, 2019, Volume: 8, Issue:3 Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Male; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Spain; Stroke; Thiazoles; Treatment Outcome	2019
Horizontal vs. vertical dose reduction of direct oral anticoagulants in patients with non-valvular atrial fibrillation: definition and implications for practice. European journal of internal medicine, 2019, Volume: 62 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Dose-Response Relationship, Drug; Embolism; Humans; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Stroke; Thiazoles	2019
Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry). The American journal of cardiology, 2019, 04-15, Volume: 123, Issue:8 Topics: Administration, Oral; Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; Japan; Male; Middle Aged; Platelet Aggregation Inhibitors; Prognosis; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Registries; Rivaroxaban; Thiazoles	2019
Edoxaban (Lixiana°). Prescrire international, 2017, Volume: 26, Issue:178 Topics: Anticoagulants; Atrial Fibrillation; Chemical and Drug Induced Liver Injury; Factor Xa Inhibitors; Hemorrhage; Humans; International Normalized Ratio; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Venous Thrombosis; Warfarin	2017
Stroke prevention in atrial fibrillation: Closing the gap. American heart journal, 2019, Volume: 210 Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Dabigatran; Health Services Misuse; Hemorrhage; Humans; International Normalized Ratio; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Warfarin	2019
Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation. Yonsei medical journal, 2019, Volume: 60, Issue:3 Topics: Administration, Oral; Aged; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Drug Labeling; Female; Humans; Male; Medication Adherence; Middle Aged; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Republic of Korea; Risk Factors; Rivaroxaban; Thiazoles; Vitamin K	2019
Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model. Heart and vessels, 2019, Volume: 34, Issue:8 Topics: Animals; Atrial Fibrillation; Atrial Remodeling; Cardiac Pacing, Artificial; Dogs; Echocardiography; Electrophysiological Phenomena; Factor Xa Inhibitors; Fibrosis; Heart Atria; Heart Failure; Pyridines; Thiazoles	2019
Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation: Update and Periprocedural Management. Critical care nurse, 2019, Volume: 39, Issue:2 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Critical Care Nursing; Dabigatran; Female; Humans; Male; Middle Aged; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Warfarin	2019
Would the Use of Edoxaban Be Cost-effective for the Prevention of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation in Spain? Revista espanola de cardiologia (English ed.), 2019, Volume: 72, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Atrial Fibrillation; Cost-Benefit Analysis; Drug Costs; Embolism; Facilities and Services Utilization; Factor Xa Inhibitors; Health Resources; Humans; Male; Middle Aged; Pyridines; Quality of Life; Quality-Adjusted Life Years; Spain; Stroke; Thiazoles	2019
The evolving obesity paradigm story: from heart failure to atrial fibrillation. European heart journal, 2019, 05-14, Volume: 40, Issue:19 Topics: Atrial Fibrillation; Body Mass Index; Heart Failure; Humans; Obesity; Pyridines; Thiazoles; Warfarin	2019
Comparison of Once-Daily Administration of Edoxaban and Rivaroxaban in Asian Patients with Atrial Fibrillation. Scientific reports, 2019, 04-30, Volume: 9, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Cause of Death; Disease Susceptibility; Drug Administration Schedule; Factor Xa Inhibitors; Female; Flow Cytometry; Follow-Up Studies; Hemorrhage; Humans; Incidence; Infant; Male; Middle Aged; Patient Outcome Assessment; Population Surveillance; Pyridines; Rivaroxaban; Thiazoles	2019
Carbamazepine interaction with direct oral anticoagulants: help from the laboratory for the personalized management of oral anticoagulant therapy. Journal of thrombosis and thrombolysis, 2019, Volume: 48, Issue:3 Topics: Anticonvulsants; Atrial Fibrillation; Carbamazepine; Drug Interactions; Drug Monitoring; Factor Xa Inhibitors; Humans; Ischemic Attack, Transient; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Thiazoles	2019
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest, 2019, Volume: 156, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Asian People; Atrial Fibrillation; Dabigatran; Databases, Factual; Female; Hemorrhage; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Retrospective Studies; Rivaroxaban; Stroke; Taiwan; Thiazoles; Thromboembolism; Treatment Outcome; Warfarin	2019
Responses of prothrombin time and activated partial thromboplastin time to edoxaban in Japanese patients with non-valvular atrial fibrillation: characteristics of representative reagents in Japan (CVI ARO 7). Heart and vessels, 2019, Volume: 34, Issue:12 Topics: Administration, Oral; Aged; Atrial Fibrillation; Biomarkers; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Partial Thromboplastin Time; Predictive Value of Tests; Prospective Studies; Prothrombin Time; Pyridines; ROC Curve; Stroke; Thiazoles; Treatment Outcome	2019
Excessive Prolongation of Coagulation Time During Treatment With Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation. The Canadian journal of cardiology, 2019, Volume: 35, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Blood Coagulation Tests; Dabigatran; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Incidence; Japan; Male; Prognosis; Pyridines; Retrospective Studies; Thiazoles; Thromboembolism	2019
Real-life Performance of Edoxaban in Elderly Patients With Atrial Fibrillation: a Multicenter Propensity Score-Matched Cohort Study. Clinical therapeutics, 2019, Volume: 41, Issue:8 Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Cohort Studies; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Propensity Score; Pyridines; Stroke; Thiazoles; Thromboembolism; Treatment Outcome; Vitamin K	2019
Continuous anticoagulation with catheter ablation: answers and questions. European heart journal, 2019, 09-21, Volume: 40, Issue:36 Topics: Anticoagulants; Atrial Fibrillation; Catheter Ablation; Humans; Pyridines; Thiazoles; Vitamin K	2019
Factors related to inappropriate edoxaban use. Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Pyridines; Renal Insufficiency; Republic of Korea; Retrospective Studies; Stroke; Thiazoles	2019
DOACs in Patients With Atrial Fibrillation and Liver Disease: Time to Expand the Safety Zone? Journal of the American College of Cardiology, 2019, 07-16, Volume: 74, Issue:2 Topics: Atrial Fibrillation; Humans; Liver Diseases; Pyridines; Thiazoles; Warfarin	2019
Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC cardiovascular disorders, 2019, 07-12, Volume: 19, Issue:1 Topics: Administration, Oral; Aged; Aged, 80 and over; Atrial Fibrillation; Drug Labeling; Drug Utilization; Europe; Factor Xa Inhibitors; Female; Guideline Adherence; Hemorrhage; Humans; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Pyridines; Registries; Risk Assessment; Risk Factors; Stroke; Thiazoles; Time Factors; Treatment Outcome	2019
Another novel oral anticoagulant matches warfarin. JAMA, 2014, Jan-15, Volume: 311, Issue:3 Topics: Anticoagulants; Atrial Fibrillation; Embolism; Hemorrhage; Humans; Pyridines; Randomized Controlled Trials as Topic; Risk; Stroke; Thiazoles; Warfarin	2014
Comparison of the phase III clinical trial designs of novel oral anticoagulants versus warfarin for the treatment of nonvalvular atrial fibrillation: implications for clinical practice. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014, Volume: 14, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Research Design; Rivaroxaban; Thiazoles; Thiophenes; Vitamin K; Warfarin	2014
Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thrombosis and haemostasis, 2014, May-05, Volume: 111, Issue:5 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials, Phase III as Topic; Dabigatran; Female; Hemorrhage; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Precision Medicine; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Survival Analysis; Thiazoles; Thiophenes; Treatment Outcome	2014
Edoxaban or standard therapy with warfarin for stroke prevention in patients with atrial fibrillation? Future cardiology, 2014, Volume: 10, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Warfarin	2014
Perioperative management of patients on new oral anticoagulants. The British journal of surgery, 2014, Volume: 101, Issue:7 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Biological Availability; Clinical Trials as Topic; Dabigatran; Drug Monitoring; Elective Surgical Procedures; Emergencies; Half-Life; Hemorrhage; Humans; Medication Adherence; Morpholines; Preoperative Care; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Time Factors; Warfarin	2014
Small-conductance calcium-activated potassium (SK) channels contribute to action potential repolarization in human atria. Cardiovascular research, 2014, Jul-01, Volume: 103, Issue:1 Topics: 1-Naphthylamine; Action Potentials; Atrial Fibrillation; Heart Atria; Heart Ventricles; Humans; Membrane Potentials; Myocardium; Myocytes, Cardiac; Pyridines; RNA, Messenger; Small-Conductance Calcium-Activated Potassium Channels; Thiazoles	2014
Direct oral anticoagulants in atrial fibrillation. Seminars in hematology, 2014, Volume: 51, Issue:2 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Embolism; Hemorrhage; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Critique of Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation trial. Stroke, 2014, Volume: 45, Issue:7 Topics: Adult; Atrial Fibrillation; Dose-Response Relationship, Drug; Double-Blind Method; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Treatment Outcome; Warfarin	2014
Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Journal of thrombosis and thrombolysis, 2015, Volume: 39, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Humans; Intracranial Hemorrhages; Italy; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Thiazoles; Warfarin	2015
Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. Stroke, 2014, Volume: 45, Issue:10 Topics: Aged; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Dabigatran; Female; Humans; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Research Design; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Warfarin	2014
Once-daily edoxaban: a safer option than well-managed warfarin for patients with atrial fibrillation? European heart journal, 2014, Jul-21, Volume: 35, Issue:28 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Drug Administration Schedule; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Stroke; Thiazoles; Warfarin	2014
Novel anticoagulants eliminate the need for left atrial appendage exclusion devices. Circulation, 2014, Oct-21, Volume: 130, Issue:17 Topics: Anticoagulants; Atrial Appendage; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Clinical Trials as Topic; Dabigatran; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Septal Occluder Device; Stroke; Thiazoles; Thiophenes; Unnecessary Procedures; Warfarin	2014
Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of medical economics, 2015, Volume: 18, Issue:6 Topics: Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Costs and Cost Analysis; Dabigatran; Health Expenditures; Hemorrhage; Humans; Models, Econometric; Myocardial Infarction; Pulmonary Embolism; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; United States; Venous Thromboembolism; Warfarin	2015
Edoxaban approved for embolism prevention. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2015, Feb-15, Volume: 72, Issue:4 Topics: Atrial Fibrillation; Drug Approval; Embolism; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; United States; United States Food and Drug Administration	2015
Should patients on vitamin K antagonists be treated differently? European heart journal, 2015, Jun-14, Volume: 36, Issue:23 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Stroke; Thiazoles; Warfarin	2015
Edoxaban and the need for outcomes-based NOAC dosing. Lancet (London, England), 2015, Jun-06, Volume: 385, Issue:9984 Topics: Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles	2015
Pharmacogenomic testing and response to warfarin. Lancet (London, England), 2015, Jun-06, Volume: 385, Issue:9984 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Warfarin	2015
Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. BioMed research international, 2015, Volume: 2015 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Cost-Benefit Analysis; Dabigatran; Germany; Humans; Pyrazoles; Pyridines; Pyridones; Quality of Life; Quality-Adjusted Life Years; Rivaroxaban; Thiazoles; Warfarin	2015
Edoxaban (Savaysa)--the fourth new oral anticoagulant. The Medical letter on drugs and therapeutics, 2015, Mar-30, Volume: 57, Issue:1465 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Embolism; Humans; Pyridines; Stroke; Thiazoles; United States; United States Food and Drug Administration; Venous Thromboembolism	2015
Cardiology patient page. Patient guide for taking the non-vitamin K antagonist oral anticoagulants for atrial fibrillation. Circulation, 2015, Apr-21, Volume: 131, Issue:16 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Contraindications; Dabigatran; Drug Interactions; Drug Monitoring; Drug Substitution; Female; Hemorrhage; Humans; Kidney Diseases; Kidney Function Tests; Male; Morpholines; Pyrazoles; Pyridines; Pyridones; Risk Factors; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombophilia	2015
Warfarin pharmacogenetics in the era of new oral anticoagulants. Clinical genetics, 2015, Volume: 88, Issue:2 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Thiazoles; Warfarin	2015
Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillation--Which Non-Vitamin K Antagonist Oral Anticoagulant to Select? Circulation journal : official journal of the Japanese Circulation Society, 2015, Volume: 79, Issue:7 Topics: Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Renal Insufficiency, Chronic; Thiazoles	2015
[Simplified therapy regimen receives recommendation for approval]. MMW Fortschritte der Medizin, 2015, Jun-11, Volume: 157, Issue:11 Topics: Atrial Fibrillation; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Embolism; Humans; Pyridines; Recurrence; Stroke; Thiazoles; Venous Thromboembolism; Warfarin	2015
Edoxaban and amiodarone: interactions on multiple levels. European heart journal, 2015, Sep-01, Volume: 36, Issue:33 Topics: Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Pyridines; Thiazoles; Warfarin	2015
The evolving role of dabigatran etexilate in clinical practice. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:13 Topics: Antithrombins; Arthroplasty, Replacement, Knee; Atrial Fibrillation; Cardiovascular Diseases; Clinical Trials as Topic; Dabigatran; Enoxaparin; Humans; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Venous Thromboembolism	2015
Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. International journal of cardiology, 2015, Dec-15, Volume: 201 Topics: Atrial Fibrillation; Dose-Response Relationship, Drug; Europe; Factor Xa Inhibitors; Female; Humans; Incidence; Male; Models, Theoretical; Population Surveillance; Pyridines; Retrospective Studies; Risk Assessment; Risk Factors; Stroke; Survival Rate; Thiazoles; Treatment Outcome	2015
[The ENGAGE AF-TIMI 48 study]. Giornale italiano di cardiologia (2006), 2015, Volume: 16, Issue:9 Topics: Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Humans; Pyridines; Randomized Controlled Trials as Topic; Thiazoles; Warfarin	2015
Cost-effectiveness of Apixaban Compared With Edoxaban for Stroke Prevention in Nonvalvular Atrial Fibrillation. Clinical therapeutics, 2015, Nov-01, Volume: 37, Issue:11 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Female; Humans; Male; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Stroke; Thiazoles	2015
Distribution of Anti-Factor Xa Activity in Patients on Edoxaban Therapy for Non-Valvular Atrial Fibrillation. Circulation journal : official journal of the Japanese Circulation Society, 2016, Volume: 80, Issue:3 Topics: Aged; Aged, 80 and over; Asian People; Atrial Fibrillation; Factor Xa Inhibitors; Female; Humans; Japan; Male; Middle Aged; Pyridines; Thiazoles	2016
[IQWiG confirms significant additional applications for edoxaban ]. MMW Fortschritte der Medizin, 2015, Dec-14, Volume: 157, Issue:21-22 Topics: Adult; Anticoagulants; Atrial Fibrillation; Drug Approval; Germany; Humans; National Health Programs; Pulmonary Embolism; Pyridines; Stroke; Thiazoles; Thromboembolism; Venous Thrombosis	2015
Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. Pharmacotherapy, 2016, Volume: 36, Issue:5 Topics: Aged; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Markov Chains; Pyridines; Quality-Adjusted Life Years; Stroke; Thiazoles; Warfarin	2016
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients. Stroke, 2016, Volume: 47, Issue:6 Topics: Administration, Oral; Aged; Anticoagulants; Atrial Fibrillation; Brain Ischemia; Cost-Benefit Analysis; Dabigatran; Humans; Insurance, Health; Middle Aged; Models, Theoretical; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Risk; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles; Warfarin	2016
Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. Journal of cardiology, 2017, Volume: 69, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Brain; Brain Ischemia; Cryosurgery; Dabigatran; Embolism; Female; Hemorrhage; Humans; Incidence; Magnetic Resonance Imaging; Male; Middle Aged; Postoperative Complications; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Warfarin	2017
Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thrombosis and haemostasis, 2016, 08-30, Volume: 116, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Clinical Trials, Phase III as Topic; Hemorrhage; Humans; Models, Statistical; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Thiazoles; Thromboembolism; Warfarin	2016
Sudden Cardiac Death in Patients With Atrial Fibrillation: Insights From the ENGAGE AF-TIMI 48 Trial. Journal of the American Heart Association, 2016, 07-08, Volume: 5, Issue:7 Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Cardiotonic Agents; Death, Sudden, Cardiac; Digitalis Glycosides; Factor Xa Inhibitors; Female; Heart Failure; Heart Rate; Humans; Hypertrophy, Left Ventricular; Incidence; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Out-of-Hospital Cardiac Arrest; Proportional Hazards Models; Protective Factors; Pyridines; Risk Factors; Stroke Volume; Thiazoles	2016
Resolving Thrombus in the Left Atrial Appendage by Edoxaban Treatment after Acute Ischemic Stroke: Report of 2 Cases. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2016, Volume: 25, Issue:10 Topics: Aged, 80 and over; Angiography, Digital Subtraction; Atrial Appendage; Atrial Fibrillation; Brain Ischemia; Cerebral Angiography; Echocardiography, Transesophageal; Factor Xa Inhibitors; Female; Humans; Magnetic Resonance Angiography; Male; Middle Aged; Pyridines; Stroke; Thiazoles; Thrombectomy; Thrombosis; Time Factors; Treatment Outcome	2016
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. European journal of heart failure, 2016, Volume: 18, Issue:9 Topics: Aged; Antithrombins; Atrial Fibrillation; Dabigatran; Factor Xa Inhibitors; Female; Glomerular Filtration Rate; Heart Failure; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Pyridones; Renal Insufficiency, Chronic; Rivaroxaban; Severity of Illness Index; Stroke; Thiazoles	2016
Management and outcomes of vaginal bleeding and heavy menstrual bleeding in women of reproductive age on direct oral anti-factor Xa inhibitor therapy: a case series. The Lancet. Haematology, 2016, Volume: 3, Issue:10 Topics: Administration, Oral; Adult; Anticoagulants; Atrial Fibrillation; Factor Xa Inhibitors; Female; Hormone Replacement Therapy; Humans; Menorrhagia; Middle Aged; Progesterone; Prospective Studies; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Thiazoles; Uterine Hemorrhage; Venous Thromboembolism	2016
Antiarrhythmic effect of the Ca Pflugers Archiv : European journal of physiology, 2016, Volume: 468, Issue:11-12 Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Drug Synergism; Guinea Pigs; Heart; Heart Rate; Isolated Heart Preparation; Phenethylamines; Potassium Channel Blockers; Pyridines; Small-Conductance Calcium-Activated Potassium Channels; Sulfonamides; Thiazoles	2016
Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function. Thrombosis research, 2017, Volume: 150 Topics: Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Cost-Benefit Analysis; Dabigatran; Hemorrhage; Humans; Markov Chains; Pyrazoles; Pyridines; Pyridones; Quality-Adjusted Life Years; Rivaroxaban; Stroke; Thiazoles; Warfarin	2017
Safety and efficacy of contemporary catheter ablation for atrial fibrillation patients with a history of cardioembolic stroke in the era of direct oral anticoagulants. Journal of cardiology, 2017, Volume: 70, Issue:1 Topics: Aged; Anticoagulants; Atrial Fibrillation; Catheter Ablation; Dabigatran; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Pulmonary Veins; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2017
Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation. Journal of women's health (2002), 2017, Volume: 26, Issue:3 Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Dabigatran; Female; Hemorrhage; Humans; Odds Ratio; Pyrazoles; Pyridines; Pyridones; Randomized Controlled Trials as Topic; Rivaroxaban; Stroke; Thiazoles; Treatment Outcome; Warfarin	2017
Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2016, Volume: 18, Issue:10 Topics: Administration, Oral; Atrial Fibrillation; Cost Savings; Cost-Benefit Analysis; Drug Costs; Europe; Factor Xa Inhibitors; Forecasting; Humans; Models, Economic; Practice Patterns, Physicians'; Pyridines; Stroke; Thiazoles; Thromboembolism; Time Factors; Treatment Outcome; Warfarin	2016
Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale. American heart journal, 2016, Volume: 182 Topics: Administration, Oral; Adult; Anticoagulants; Antithrombins; Atrial Fibrillation; Cohort Studies; Dabigatran; Emergency Treatment; Female; Humans; Male; Medication Therapy Management; Outcome and Process Assessment, Health Care; Pyrazoles; Pyridines; Pyridones; Quality Improvement; Registries; Rivaroxaban; Stroke; Thiazoles; United States; Warfarin	2016
Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment. Clinical pharmacology in drug development, 2017, Volume: 6, Issue:5 Topics: Administration, Oral; Atrial Fibrillation; Clinical Trials as Topic; Creatinine; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Humans; Japan; Male; Metabolic Clearance Rate; Pyridines; Renal Insufficiency; Thiazoles	2017
Edoxaban Versus Warfarin: Bone Fractures Due to Falling. Journal of the American College of Cardiology, 2017, 01-31, Volume: 69, Issue:4 Topics: Accidental Falls; Atrial Fibrillation; Fractures, Bone; Humans; Pyridines; Thiazoles; Warfarin	2017
Italian intersociety consensus on DOAC use in internal medicine. Internal and emergency medicine, 2017, Volume: 12, Issue:3 Topics: Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Clinical Competence; Consensus; Dabigatran; Drug-Related Side Effects and Adverse Reactions; Factor Xa Inhibitors; Food-Drug Interactions; Humans; Internal Medicine; Italy; Liver Diseases; Perioperative Period; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Time Factors; Venous Thromboembolism	2017
P wave and QT changes among inpatients with schizophrenia after parenteral ziprasidone administration. Pharmacological research, 2009, Volume: 60, Issue:5 Topics: Adult; Antipsychotic Agents; Atrial Fibrillation; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Schizophrenia; Thiazoles	2009
Inhibition of small-conductance Ca2+-activated K+ channels terminates and protects against atrial fibrillation. Circulation. Arrhythmia and electrophysiology, 2010, Volume: 3, Issue:4 Topics: 1-Naphthylamine; Acetylcholine; Action Potentials; Alkanes; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing, Artificial; Dose-Response Relationship, Drug; Electrocardiography; Female; Guinea Pigs; In Vitro Techniques; Male; Myocardium; Perfusion; Potassium Channel Blockers; Potassium Channels, Calcium-Activated; Pyridines; Quinolinium Compounds; Rabbits; Rats; Rats, Sprague-Dawley; Thiazoles; Time Factors	2010
Factor Xa and thrombin as targets for new oral anticoagulants. Thrombosis research, 2011, Volume: 127 Suppl 2 Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Atrial Fibrillation; Benzimidazoles; Clinical Trials as Topic; Dabigatran; Drug Discovery; Factor Xa Inhibitors; Humans; Morpholines; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Stroke; Thiazoles; Thiophenes; Thrombin; Venous Thromboembolism; Vitamin K	2011
Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future cardiology, 2011, Volume: 7, Issue:4 Topics: Anticoagulants; Atrial Fibrillation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Stroke; Thiazoles; Venous Thromboembolism	2011
Edoxaban: a new oral direct factor xa inhibitor. Drugs, 2011, Aug-20, Volume: 71, Issue:12 Topics: Administration, Oral; Animals; Anticoagulants; Atrial Fibrillation; Blood Coagulation; Clinical Trials as Topic; Factor Xa Inhibitors; Humans; Pyridines; Rabbits; Rats; Stroke; Thiazoles; Venous Thrombosis	2011
Subacute ischemic stroke is associated with focal 11C PiB positron emission tomography retention but not with global neocortical Aβ deposition. Stroke, 2012, Volume: 43, Issue:5 Topics: Aged; Amyloid beta-Peptides; Aniline Compounds; Atrial Fibrillation; Brain Infarction; Carbon Radioisotopes; Case-Control Studies; Diabetes Complications; Female; Humans; Hyperlipidemias; Hypertension; Male; Neocortex; Phenanthrolines; Positron-Emission Tomography; Risk Factors; Smoking; Stroke; Thiazoles	2012
Edoxaban in Japanese patients with nonvalvular atrial fibrillation: not the same dose for everybody. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:8 Topics: Anticoagulants; Atrial Fibrillation; Female; Humans; Male; Pyridines; Thiazoles; Warfarin	2012
Oral anticoagulation for ECG tremor artefact simulating atrial fibrillation. Acta cardiologica, 2003, Volume: 58, Issue:5 Topics: Aged; Anticoagulants; Antiparkinson Agents; Atrial Fibrillation; Benzothiazoles; Diagnosis, Differential; Diagnostic Errors; Electrocardiography; Female; Humans; Parkinson Disease; Phenprocoumon; Pramipexole; Thiazoles	2003
R56865 is antifibrillatory in reperfused ischemic guinea-pig hearts, even when given only during reperfusion. Cardiovascular drugs and therapy, 1995, Volume: 9, Issue:4 Topics: Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzothiazoles; Calcium; Calcium Channel Blockers; Extracellular Space; Guinea Pigs; Heart; In Vitro Techniques; Lidocaine; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Piperidines; Potassium; Sodium; Thiazoles; Verapamil	1995